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A B S T R A C T
Background
Ulcerative colitis is an inflammatory condition aKecting the colon, with an annual incidence of approximately 10 to 20 per 100,000
people. The majority of people with ulcerative colitis can be put into remission, leaving a group who do not respond to first- or second-
line therapies. There is a significant proportion of people who experience adverse eKects with current therapies. Consequently, new
alternatives for the treatment of ulcerative colitis are constantly being sought. Probiotics are live microbial feed supplements that
may beneficially aKect the host by improving intestinal microbial balance, enhancing gut barrier function and improving local immune
response.
Objectives
To assess the eKicacy of probiotics compared with placebo or standard medical treatment (5-aminosalicylates, sulphasalazine or
corticosteroids) for the induction of remission in people with active ulcerative colitis.
Search methods
We searched CENTRAL, MEDLINE, Embase, and two other databases on 31 October 2019. We contacted authors of relevant studies and
manufacturers of probiotics regarding ongoing or unpublished trials that may be relevant to the review, and we searched ClinicalTrials.gov.
We also searched references of trials for any additional trials.
Selection criteria
Randomised controlled trials (RCTs) investigating the eKectiveness of probiotics compared to standard treatments or placebo in the
induction of remission of active ulcerative colitis. We considered both adults and children, with studies reporting outcomes of clinical,
endoscopic, histologic or surgical remission as defined by study authors
Data collection and analysis
Two review authors independently conducted data extraction and 'Risk of bias' assessment of included studies. We analysed data using
Review Manager 5. We expressed dichotomous and continuous outcomes as risk ratios (RRs) and mean diKerences (MDs) with 95%
confidence intervals (CIs). We assessed the certainty of the evidence using the GRADE methodology.
Main results
In this review, we included 14 studies (865 randomised participants) that met the inclusion criteria. Twelve of the studies looked at adult
participants and two studies looked at paediatric participants with mild to moderate ulcerative colitis, the average age was between 12.5
and 47.7 years. The studies compared probiotics to placebo, probiotics to 5-ASA and a combination of probiotics plus 5-ASA compared to
5-ASA alone. Seven studies used a single probiotic strain and seven used a mixture of strains. The studies ranged from two weeks to 52
weeks. The risk of bias was high for all except two studies due to allocation concealment, blinding of participants, incomplete reports of
outcome data and selective reporting. This led to GRADE ratings of the evidence ranging from moderate to very low.
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Probiotics versus placebo
Probiotics may induce clinical remission when compared to placebo (RR 1.73, 95% CI 1.19 to 2.54; 9 studies, 594 participants; low-certainty
evidence; downgraded due to imprecision and risk of bias, number needed to treat for an additional beneficial outcome (NNTB) 5).
Probiotics may lead to an improvement in clinical disease scores (RR 2.29, 95% CI 1.13 to 4.63; 2 studies, 54 participants; downgraded due
to risk of bias and imprecision).
There may be little or no diKerence in minor adverse events, but the evidence is of very low certainty (RR 1.04, 95% CI 0.42 to 2.59; 7 studies,
520 participants). Reported adverse events included abdominal bloating and discomfort. Probiotics did not lead to any serious adverse
events in any of the seven studies that reported on it, however five adverse events were reported in the placebo arm of one study (RR 0.09,
CI 0.01 to 1.66; 1 study, 526 participants; very low-certainty evidence; downgraded due to high risk of bias and imprecision). Probiotics may
make little or no diKerence to withdrawals due to adverse events (RR 0.85, 95% CI 0.42 to 1.72; 4 studies, 401 participants; low-certainty
evidence).
Probiotics versus 5-ASA
There may be little or no diKerence in the induction of remission with probiotics when compared to 5-ASA (RR 0.92, 95% CI 0.73 to 1.16;
1 study, 116 participants; low-certainty evidence; downgraded due to risk of bias and imprecision). There may be little or no diKerence in
minor adverse events, but the evidence is of very low certainty (RR 1.33, 95% CI 0.53 to 3.33; 1 study, 116 participants). Reported adverse
events included abdominal pain, nausea, headache and mouth ulcers. There were no serious adverse events with probiotics, however
perforated sigmoid diverticulum and respiratory failure in a patient with severe emphysema were reported in the 5-ASA arm (RR 0.21, 95%
CI 0.01 to 4.22; 1 study, 116 participants; very low-certainty evidence).
Probiotics combined with 5-ASA versus 5-ASA alone
Low-certainty evidence from a single study shows that when combined with 5-ASA, probiotics may slightly improve the induction of
remission (based on the Sunderland disease activity index) compared to 5-ASA alone (RR 1.22 CI 1.01 to 1.47; 1 study, 84 participants; low-
certainty evidence; downgraded due to unclear risk of bias and imprecision). No information about adverse events was reported.
Time to remission, histological and biochemical outcomes were sparsely reported in the studies. None of the other secondary outcomes
(progression to surgery, need for additional therapy, quality of life scores, or steroid withdrawal) were reported in any of the studies.
Authors' conclusions
Low-certainty evidence suggests that probiotics may induce clinical remission in active ulcerative colitis when compared to placebo. There
may be little or no diKerence in clinical remission with probiotics alone compared to 5-ASA. There is limited evidence from a single study
which failed to provide a definition of remission, that probiotics may slightly improve the induction of remission when used in combination
with 5-ASA. There was no evidence to assess whether probiotics are eKective in people with severe and more extensive disease, or if specific
preparations are superior to others. Further targeted and appropriately designed RCTs are needed to address the gaps in the evidence
base. In particular, appropriate powering of studies and the use of standardised participant groups and outcome measures in line with the
wider field are needed, as well as reporting to minimise risk of bias.
P L A I N   L A N G U A G E   S U M M A R Y
Probiotics for the treatment of active ulcerative colitis
What is the aim of this review?
The aim of this Cochrane Review was to find out whether probiotics can induce remission in people with ulcerative colitis. We analysed
data from 14 studies to answer this question.
Key messages
Probiotics may be better at inducing remission than placebo (dummy treatment). It is unclear whether probiotics are better than 5-
aminosalicylic acid (5-ASA, an anti-inflammatory agent used to treat inflammatory bowel disease), however there is limited evidence that
when both treatments are used as combined therapy they may be better than 5-ASA alone in inducing remission. Most studies reported
that no serious adverse events took place. For the studies that did report on it, serious adverse events did not occur in the probiotic group.
Minor adverse events reported were bloating and diarrhoea.
What was studied in the review?
Ulcerative colitis is a relapsing and remitting disease which causes inflammation of the large bowel and leads to symptoms such as
abdominal pain, diarrhoea and tiredness. There is some evidence to suggest that an imbalance in the bacteria of the gut is the cause of the
disease, and therefore probiotics, which are live micro-organisms, can alter the bacteria and possibly reduce the inflammation.
What are the main results of the review?
Probiotics for induction of remission in ulcerative colitis (Review)
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We searched for randomised controlled trials (RCTs; clinical studies where people are randomly put into one of two or more treatment
groups) comparing probiotics with placebo, probiotics with 5-ASA, and probiotics in combination with 5-ASA. We found 14 RCTs looking
at 865 participants. The trials looked at adult and paediatric participants. Eight studies allowed additional therapy to continue, whilst the
other four studies were unclear about this.
1) Probiotics may improve induction of clinical remission when compared to placebo.
2) It is unclear whether probiotics lead to a diKerence in adverse events (minor and serious) when compared to placebo.
3) There is limited evidence to determine whether probiotics oKer better disease improvement when compared to placebo.
4) There may be little or no diKerence in the induction of remission with probiotics when compared to 5-ASA (low-certainty evidence).
5) There is limited evidence to suggest that when probiotics plus 5-ASA are compared to 5-ASA alone, probiotics may oKer a slightly better
chance of induction of remission. This is based on low-certainty evidence from one study, and we are not sure of the type of remission
studied.
6) Serious adverse events were reported when probiotics were compared with placebo, but only occurred in the placebo group.
Conclusion
Whilst the evidence suggests that probiotics may be better at improving induction than placebo, our confidence in the estimate is limited
because of the low-certainty evidence. This is attributed to the small number of participants in each study along with the unreliable
methods utilised by the trials. With the evidence presented in these studies, we are unable to make strong conclusions into the eKectiveness
of probiotics; better designed studies with more participants are needed.
How up-to-date is this review?
This review is up-to-date as of October 2019.
Probiotics for induction of remission in ulcerative colitis (Review)





































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Probiotics compared to placebo for induction of remission in ulcerative colitis
Probiotics compared to placebo for induction of remission in ulcerative colitis (follow-up 2 to 52 weeks)































Remission was defined as the absence of rectal bleeding, a rectal
mucosa without erythaema, granularity, or friability and normal
or near-normal sigmoidoscopic findings (Kato 2004); clinical DAI ≤
2 (Matthes 2010); occurrence or worsening of symptoms, accom-
panied by an increase in LCAI > 3, sufficient to require treatment
with corticosteroids, azathioprine/immunosuppressive agents or
surgery (Miele 2009); final DAI score < 2 (Oliva 2011); UCDAI scores
of 0-2 (Tamaki 2016); UCDAI score < 2 (Tursi 2010); not having more
than three well-formed stools per day and without visible blood
in the stools and any clinical symptoms of ulcerative colitis and
had a clinical activity index < 4 (Vejdani 2017); remission was based
on UCDAI, however, no further information was provided (Sood
2009), bloody diarrhoea, without tachycardia, without fever, with-














One additional RCT (144 participants) showed that probiotics im-












Adverse events reported were gastrointestinal disorders, unpleas-










































































































































Aggravated proctosigmoiditis was reported in the placebo group
in one study as the only adverse event. No other study provided
further details.
Study populationWithdraw-
al due to ad-








No study provided details on the adverse events leading to with-
drawal from trial.
*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its
95% CI).
CI: confidence interval; CRP: c-reactive protein; DAI; disease activity index; ESR: erythrocyte sedimentation rate; LCAI: Lichtiger colitis activity index; RCT: randomised con-
trolled trial; RR: risk ratio; UCDAI: ulcerative colitis disease activity index
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two times for high risk of bias in most of the studies and serious imprecision due to sparse data. We did not downgrade for inconsistency (substantial heterogeneity,
I2 = 66%) as eKect estimates were fairly consistent across studies and heterogeneity was attributed to the diKerences in probiotic preparation.
2bDowngraded three times for risk of bias, very serious inconsistency (substantial heterogeneity, I2 = 69%) and very serious imprecision due to CIs which include a risk of benefit
and harm.
cDowngraded three times for risk of bias and very serious imprecision as CI includes a risk of benefit and harm.
dDowngraded two times for very serious imprecision as CI includes a risk of benefit and harm.
 
 
Summary of findings 2.   Probiotics compared to 5-aminosalicylic acid (5-ASA) (mesalazine) for induction of remission in ulcerative colitis
Probiotic compared to 5-ASA for induction of remission in ulcerative colitis (52 weeks follow-up; one study unclear)



























































































































































Remission was defined as general well-being with the pas-
sage of no more than three formed stools per day, a rectal












Minor adverse events were abdominal pain, nausea,
headache and mouth ulcer.
Study populationSerious ad-
verse events








Serious adverse events reported were perforated sigmoid
diverticulum and respiratory failure in a patient with severe
emphysema.
Study populationWithdraw-
al due to ad-








Withdrawals were due to perforated sigmoid diverticulum




*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its
95% CI).
5-ASA: 5-aminosalicylates; CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two times for risk of other bias (participants were classified according to disease severity and given specific concomitant treatments based on this classification,
this puts the randomisation into question) and serious imprecision due to small sample size in a single study.
b Downgraded two times for risk of other bias; (participants were classified according to disease severity and given specific concomitant treatments based on this classification,

































































































































Summary of findings 3.   Probiotics plus 5-aminosalicylic acid (5-ASA) (mesalazine) compared to 5-aminosalicylic acid (5-ASA) (mesalazine) for
induction of remission in ulcerative colitis
Probiotics plus 5-ASA compared to 5-ASA for induction of remission in ulcerative colitis (follow-up 4 weeks to 24 months)
Patient or population: people with active ulcerative colitis
Setting: hospitals
Intervention: probiotic plus 5-ASA
Comparison: 5-ASA
Anticipated absolute effects* (95% CI)Outcomes





















based on the Sunder-
land activity score
Disease improvement Not reported
Minor adverse events Not reported
Serious adverse events Not reported
Withdrawal due to adverse
events
Not reported
*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its
95% CI).
5-ASA: 5-aminosalicylic acid; CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
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B A C K G R O U N D
Description of the condition
Ulcerative colitis is a chronic relapsing disease, with the greatest
reported incidence in mainland Europe and Scandinavia of 9.2
to 20.3 per 100,000 people (LoTus 2004), totalling approximately
2.2 million suKerers in Europe alone. The peak incidence of
the disease occurs between 15 and 25 years of age and there
is another smaller prevalence at ages 55 to 65. The disease is
characterised by abdominal pain, bloody diarrhoea and faecal
urgency. The diagnosis of ulcerative colitis is made on the basis
of medical history, signs and symptoms, and any endoscopic or
histopathological findings.
The disease is caused by diKuse inflammation, which starts at
the rectum, spreads proximally, and is limited to the colon.
The aetiology of the disease is unknown, but is likely to be
multifactorial; consisting of a genetic predisposition, dysregulation
of the mucosal and epithelial barrier and lastly dysbiosis, although
whether dysbiosis causes or is a result of the disease remains
unclear (Ungaro 2016). The genetic predisposition creates a four-
fold risk for first-degree relatives.
Description of the intervention
Probiotics are live micro-organisms, that when consumed, may
provide multiple health benefits. They produce their benefits by
altering the gut microbiome through either enhancing the activity,
volume or both, of the normal flora. Lactobacillus spp, for example,
is one of the more popular probiotics and is thought to secrete
bacteriocin, blocking the adherence or translocation of harmful
bacteria (Panigrahi 2014).
Lactobacillus rhamnosus GG (L rhamnosus GG) produced mixed
responses in animal models of colitis (Dieleman 2003; Shibolet
2002), as did Lactobacillus plantarum (L plantarum) 299V
(Dieleman 2003; Kennedy 2000; Schultz 2002). Studies investigating
combinations of probiotic species incorporated within VSL#3 have
demonstrated a partial reduction of colitis in animal models
(Madsen 2001; Shibolet 2002). There has been increasing interest
in the use of probiotics, as they are considered safe and easily
accessible (Ong 2019). It is worth noting that there are a huge
number of diKerent preparations available, varying in the specific
strains isolated, the use of mixed strains in a single preparation,
the form of the preparation and finally the licensing arrangements
surrounding the preparations (medicinal versus food products).
How the intervention might work
There is growing evidence looking at the eKects of probiotics in
the use of inducing remission in ulcerative colitis since a previous
Cochrane review (Mallon 2007). Due to the part that dysbiosis
plays in ulcerative colitis, there is potential benefit in trying to
restore the indigenous flora. Several observations, both on humans
and animal models, emphasised the importance of bacterial
flora in inflammatory bowel disease pathogenesis, justifying the
current interest in antibiotic and probiotic therapies, aimed at
the manipulation of enteric flora (Cui 2004). The therapeutic
eKicacy of probiotics has been demonstrated in various models
of experimental colitis, including interleukin-10 deficient mice
(Madsen 1999; Schultz 2002), and acetic acid-induced colitis in rats
(Fabia 1993).
Why it is important to do this review
In the UK, National Institute for Health and Care Excellence (NICE)
and USA guidelines state that first-line therapy for maintenance
of remission in ulcerative colitis is 5-aminosalicylic acid (5-ASA)
(NICE 2013). 5-ASA works by binding to PPAR-# and reducing
cytokine production. Some of the adverse eKects associated with
5-ASA include headache, rash, nausea (common), pancreatitis
(uncommon), and agranulocytosis (rare). Due to these side eKects,
some people are unable to tolerate the drug. If 5-ASA fails to provide
any relief then steroids can be added as an adjunct. Steroids, such
as prednisolone, can also be used alone, however if aTer two to
four weeks an adequate response is not observed, then immune
suppressant therapies, such as anti-tumour necrosis factor (TNF)
monoclonals, vedolizumab and tofacitinib may be used to induce
remission. These drugs work by blocking leukocyte recruitment
at the molecular and vascular level (Fiorino 2016), some of the
side eKects include headache, dizziness and arthralgia. Despite
these medications, failure to induce remission occurs in 20% to
30% of people on current treatments, with a proportion of patients
eventually requiring colectomy. Consequently, new alternatives for
the treatment of ulcerative colitis are constantly being sought.
The relapsing and remitting nature of the disease means that
people can be in and out of hospital, experimenting with diKerent
drug regimens. The treatment costs Europe between GBP 11 to 26
billion annually, with per patient costs approximately GBP 8011
to 9306 (Cohen 2010). If an alternative, cheaper treatment can be
found for ulcerative colitis, then it would greatly benefit not only
a budget stricken National Health Service (NHS), but also improve
patients' quality of life. Whilst some studies have suggested that
probiotics may be useful for maintenance of remission in mild to
moderate ulcerative colitis (Kruis 2004; Zocco 2006), others have
failed to show any benefit (Kruis 1997; Rembacken 1999). The
previous published form of this review is more than 10 years old
(Mallon 2007), and did not consider a paediatric population. As
the burden of ulcerative colitis is shared within this population
as well, consideration of studies in this group of patients would
provide a greater understanding as to whether the intervention
works diKerently in adults compared to children. In this review, we
investigated the available evidence on the use of probiotics for the
induction of remission in ulcerative colitis.
O B J E C T I V E S
To assess the eKicacy of probiotics compared with placebo
or standard medical treatment (5-aminosalicylic acid (5-ASA),
sulphasalazine or corticosteroids) for the induction of remission in
people with active ulcerative colitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
People of any age with active ulcerative colitis previously diagnosed
by clinical, endoscopic, histologic or surgical remission as defined
by study authors
Probiotics for induction of remission in ulcerative colitis (Review)
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Types of interventions
RCTs comparing probiotics administered in any form (drink,
powder, capsule) orally as a single species or as a cocktail of
multiple species, versus placebo, probiotics standard therapy (e.g.
5-aminosalicylic acid (5-ASA), sulfasalazine or corticosteroids),
or probiotics used in conjunction with standard therapy versus
standard therapy for the induction of remission in active ulcerative
colitis.
Types of outcome measures
Primary outcomes
• Remission (clinical, endoscopic, histologic or surgical remission,
as defined by study authors)
Secondary outcomes
• Disease improvement (clinical or endoscopic, as defined by
study authors)
• Steroid withdrawal
• Clinical activity scores
• Histology scores
• Biochemical markers of inflammation
• Need for additional therapy
• Progression to surgery
• Symptomatic severity (stool frequency, abdominal pain)
• Quality of life scores
• Time to remission/improvement
• Minor adverse events
• Serious adverse events
• Withdrawal due to adverse events
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status.
Electronic searches
We conducted a comprehensive and systematic search to identify
RCTs from inception to 31 October 2019, using the following
databases.
• Cochrane Inflammatory Bowel Disease Group Specialized Trials
Register




We did not place restrictions on publication dates (aTer 1966) or
language. We reported the detailed search strategies in Appendix 1.
Searching other resources
We inspected the reference lists of all identified studies for
additional trials. We also contacted leaders in the field and
manufacturers of probiotics to identify potentially relevant
studies. We also searched ClinicalTrials.gov for ongoing trials
(clinicaltrials.gov).
Data collection and analysis
Selection of studies
We undertook study selection in Covidence.
Using the above search strategy, two review authors (LK,
MG) identified titles that appeared to be potentially relevant.
These were independently screened and in circumstances of
disagreement, a third review author (AA) was involved to reach
consensus.
There is some evidence that data from abstract publications can
be inconsistent with data from published articles (Pitkin 1999),
therefore we considered abstract publications, but only if suKicient
data were presented to judge inclusion criteria fully and reports
of the primary and secondary outcomes were given. If these were
not available, we contacted authors directly, and if data were not
provided, we excluded such studies.
The review authors, aTer reading the full texts, independently
assessed the eligibility of all trials identified using ad hoc eligibility,
based on the inclusion criteria above. Disagreement among review
authors was again discussed, and agreement was reached by
consensus aTer involvement of a third review author. We contacted
authors of multiple publications, which appeared to report on the
same study, for clarification. A flow chart was included (Figure 1).
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Figure 1.   Study flow diagram
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Figure 1.   (Continued)
 
Data extraction and management
Two review authors (LK and MG) carried out data extraction
independently by using piloted forms. The data collected included
information on the study design, participants, intervention and
comparator, as well as outcome. Discrepancies in data extraction
were discussed and if necessary, a third review author was
consulted. LK and MG then entered data into the review file.
Assessment of risk of bias in included studies
The review authors (LK and MG) independently carried out 'Risk
of bias' assessment of the included studies. We used the Cochrane
'Risk of bias' tool in assessing the following domains (Higgins 2011).
• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessors
• Completeness of outcome data
• Selective reporting
• Other sources of bias
We considered subjective outcomes separately in our assessment
of blinding and incompleteness of data. We judged studies to be at
'high', 'low' or 'unclear' risk of bias for each domain assessed. We
judged the risk of bias across studies as follows.
• Low risk of bias (plausible bias unlikely to seriously alter the
results) if all domains are at low risk of bias.
• Unclear risk of bias (plausible bias that raises some doubt about
the results) if one or more domains are at unclear risk of bias.
• High risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more domains are at high risk
of bias.
Disagreements were resolved by consensus. We contacted study
authors when insuKicient information was provided to determine
the risk of bias. Where we obtained information supporting our
judgement on risk of bias through correspondence with study
authors, we indicated this in the 'Risk of bias' table.
Measures of treatment e<ect
We expressed the treatment eKect of dichotomous outcomes as
risk ratios (RRs) and continuous outcomes as mean diKerences
(MDs). In future updates, where studies measure the same outcome
using diKerent scales, we will express continuous outcomes as
standardised mean diKerences (SMDs). For continuous data, we
preferred final scores to change scores. We planned to express time
to remission as median or hazard ratio (HR), but as data were not
suKiciently reported this was unnecessary.
Unit of analysis issues
The participant was the unit of analysis. We dealt with studies
involving multiple trial arms according to methods proposed in
Higgins 2011 (Section 16.5.4). We did not combine groups, but
rather we used relevant groups as per the appropriate pair wise
comparison. We considered unit of analysis issues arising from the
measurement of outcomes at diKerent time points.
Dealing with missing data
We contacted study authors for missing data. Where possible,
we applied intention-to-treat analysis. We calculated missing
standard deviations (SDs) from other reported data (such as P
values, confidence intervals (CIs) and standard errors), where
possible. However, we imputed missing data. If data was recorded
from a graph, this was stated. In reporting adverse events, we
assumed 'worst case' to avoid under reporting. For instance, we
assumed that minor and serious adverse events were related to the
intervention.
Assessment of heterogeneity
The decision to pool the results of individual studies depended on
an assessment of clinical and methodological heterogeneity. If we
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considered studies suKiciently homogeneous for data pooling, we
assessed statistical heterogeneity by visual inspection of the forest
plots, and using the Chi2 test with a significance level at P < 0.1 and
the I2 statistic. We based our interpretation of the I2 statistic results
on those suggested by Higgins 2011 (Section 9.5.2):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%; may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We avoided various reporting biases by undertaking an extensive
literature search without restrictions on publication date or
language. We used study protocols and trial registrations in
assessing studies for selective reporting. If we had more than 10
studies, we would have generated a funnel plot. The magnitude
of publication bias would have been initially determined by visual
inspection of the asymmetry of the funnel plot. If this appeared
asymmetric, we would have performed a linear regression of
intervention eKect estimate against its standard error, weighted by
the inverse of the variance of the intervention eKect estimate (Egger
1997). P < 0.1 would be an indication of a publication bias or small-
study eKect.
Data synthesis
We analysed data using Review Manager 5 (Review Manager 2014).
For dichotomous outcomes, we derived RRs and 95% CIs for each
study. For continuous outcomes, we derived MDs and 95% CIs.
We combined the results of included studies for each outcome if
appropriate. We used either fixed-eKect or random-eKects models,
depending on the presence of statistical heterogeneity and the
number or size of studies available. We considered not pooling data
where there was considerable heterogeneity (I2 ≥ 75%) which was
not explained by clinical or methodological diKerences between
the studies. However, we presented data which we were unable to
pool as a narrative summary.
Subgroup analysis and investigation of heterogeneity
We attempted to investigate unexplained heterogeneity. We
checked the data, adjusted for heterogeneity by using a random-
eKects model and then changed the measure of treatment eKects
from RR to odds ratios (OR), as proposed in section 9.5.3 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We undertook the following subgroup analyses.
• Paediatric versus adult population
• Single versus multiple strain probiotics
Sensitivity analysis
We undertook sensitivity analyses to assess whether results of the
review are robust to the decisions which were taken during the
review process. We examined the eKect on the review findings of:
• excluding studies at high risk of bias; and
• comparing the use of fixed-eKect versus random-eKects models.
Summary of findings and assessment of the certainty of the
evidence
We used the GRADE approach to assess the certainty of evidence
related to the primary outcomes listed in Types of outcome
measures (Schünemann 2011). The four levels of evidence certainty
are 'high', 'moderate', 'low' or 'very low'. We downgraded the
certainty of evidence due to study limitations (risk of bias),
imprecision, inconsistency, indirectness or publication bias.
Where there was suKicient evidence, we prepared 'Summary of
findings' tables for our main comparisons; we presented the results
for remission, disease improvement and adverse events. Two
review authors (LK and MG) independently produced 'Summary of
findings' tables using the GRADEpro GDT soTware (GRADEpro GDT
2015).
R E S U L T S
Description of studies
Results of the search
The literature search conducted in December 2017 and updated
in November 2019 provided 1302 studies once duplicates were
removed, and one study identified through the previous review was
added. Once we screened the titles and abstracts, and removed
further duplicates, we found 35 studies that met the inclusion
criteria. Full-text copies were available for 33 of these studies.
Further scrutiny identified 14 studies that met the inclusion criteria
and we excluded 11 studies with reasons. We contacted authors of
all 14 included studies (Kato 2004; Li 2013; Liu 2014; Matthes 2010;
Miele 2009; Oliva 2011; Rembacken 1999; Sanchez-Morales 2019;
Solovyeva 2014; Sood 2009; Tamaki 2016; Tursi 2010; Vejdani 2017;
Zhang 2018a); two authors replied (Sanchez-Morales 2019; Sood
2009).
We identified one ongoing study and six studies are awaiting
classification (Characteristics of ongoing studies; Characteristics of
studies awaiting classification).
The results of the search are presented in the PRISMA diagram
(Figure 1). Full details of the included and excluded studies
are available in the Characteristics of included studies and
Characteristics of excluded studies.
Included studies
Study design and setting
We included 14 studies published between 1999 and 2019 (Kato
2004; Li 2013; Liu 2014; Matthes 2010; Miele 2009; Oliva 2011;
Rembacken 1999; Sanchez-Morales 2019; Solovyeva 2014; Sood
2009; Tamaki 2016; Tursi 2010; Vejdani 2017; Zhang 2018a).
These studies were either single-centred (Li 2013; Miele 2009;
Oliva 2011; Sanchez-Morales 2019; Zhang 2018a), or multicentred
(Kato 2004; Matthes 2010; Sood 2009; Tamaki 2016; Tursi 2010)
parallel group RCTs. In two of these studies (Liu 2014; Solovyeva
2014), it was unclear whether they were single- or multicentred.
The studies were conducted in China (Li 2013; Liu 2014; Zhang
2018a), Japan (Kato 2004; Tamaki 2016), Mexico (Sanchez-Morales
2019), Germany (Matthes 2010), Italy (Miele 2009; Oliva 2011), UK
(Rembacken 1999), Iran (Vejdani 2017) and India (Sood 2009). For
two studies, it is unclear where the studies took place and therefore
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we have assumed this to be the authors' aKiliation and included
Solovyeva 2014 (Russia) and Tursi 2010 (Italy).
Participants
The average age of participants was between 12.5 years in Oliva
2011 and 47.7 years in Tursi 2010. Only three studies reported age
ranges and two of these were looking at paediatric participants;
1.7 years in Miele 2009 to 18 years in Oliva 2011. The studies
randomised 20 participants in Kato 2004 to 147 in Sood 2009, and
had a mixture of male and females. One study did not mention
the number of participants it had nor the demographics of the
participants (Solovyeva 2014). All participants may or may not have
been receiving medication concurrently in the studies. Five studies
described the extent of disease in participants, which included
proctitis, leT colon involved, proctosigmoiditis and total/subcolitis
(Kato 2004; Miele 2009; Sood 2009; Tamaki 2016; Tursi 2010).
Two studies reported on smoking amongst participants (Matthes
2010; Sanchez-Morales 2019). Five studies used either clinical,
endoscopic, histological and/or radiological criteria to confirm that
its participants had active colitis on recruitment (Kato 2004; Liu
2014; Miele 2009; Oliva 2011; Tamaki 2016). Only one study provided
information that its participants had disease duration of more than
five years (Oliva 2011).
Interventions
All of the included studies had two trial arms, apart from Li 2013
and Matthes 2010, with four arms. Matthes 2010 had three probiotic
arms with increasing strengths and one control group. Li 2013 had
one trial arm with probiotics, one with conventional treatment, one
with a combination, and one control group that received nothing.
The studies investigated the following comparisons.
• Probiotic versus placebo (Kato 2004; Matthes 2010; Miele 2009;
Oliva 2011; Sanchez-Morales 2019; Sood 2009; Tamaki 2016;
Tursi 2010; Vejdani 2017).
• Probiotic versus 5-aminosalicylic acid (5-ASA) (Rembacken
1999; Zhang 2018a).
• Probiotic and 5-ASA versus 5-ASA (Liu 2014; Solovyeva 2014).
• Probiotic and 5-ASA versus 5-ASA versus probiotic versus
nothing (Li 2013).
Single strains of bacteria were tested in seven studies (Matthes
2010; Oliva 2011; Rembacken 1999; Solovyeva 2014; Tamaki
2016; Vejdani 2017; Zhang 2018a). The other seven tested
multiple strains. The single strains of bacteria that were tested
include Echerichia coli (E coli) strain Nissle 1917 (Matthes 2010),
Lactobacillus reuteri (L reuteri) ATCC 55730 (Oliva 2011), E
Coli (serotype 06:K5:H1) (Rembacken 1999), Bifidobacterium 536
(Tamaki 2016), L casei strain ATCC PTA-3945 (Vejdani 2017),
Enteroccus faecium (E faecium) L-3 (Solovyeva 2014).
We studied the following combinations.
• Six strains ofLactobacillus plantarum (L plantarum),
Lactobacillus acidophilus (L acidophilus), Lactobacillus
rhamnosus (L rhamnosus), Lactobacillus bifidus (L bifidus), L casei
andBifidobacterium infantis (B infantis) (Sanchez-Morales 2019).
• Bifidobacterium breve (B breve), Bifidobacterium bifidum (B
bifidum) andLactobacillus acidophilus (L acidophilus) YIT 0168
(Kato 2004).
• Four strains of Lactobacillus (L paracasei, L plantarum, L
acidophilus, L delbrueckii subsp bulgaricus), three strains
ofBifidobacterium (B longum, B breve andB infantis), and one
strain of Streptococcus salivaria (S salivaria) subsp thermophiles
(Miele 2009; Sood 2009; Tursi 2010).
• Four and three strains of Bifidobacterium in Zhang 2018a and Liu
2014, respectively.
• Two strains of probiotic and one strain of prebiotic
(Bifidobacterium (B bifidum), lactobacillus bulgaricus (L
bulgaricus), streptococcus thermophilus (S thermophilus)) (Li
2013).
Interventions were administered daily for two weeks in Matthes
2010 to 52 weeks in Miele 2009. Concomitant treatments were used
in nine studies (Matthes 2010; Miele 2009; Oliva 2011; Rembacken
1999; Sanchez-Morales 2019; Sood 2009; Tamaki 2016; Tursi 2010;
Vejdani 2017), and it was unclear in the other four studies
if concomitant treatment was allowed. Concomitant treatment
ranged from loperamide drops (Matthes 2010), gentamicin for one
week (Rembacken 1999), oral 5-ASA (Oliva 2011; Sanchez-Morales
2019), oral 5-ASA, azathioprine and 6-mercaptopurine (Sood 2009;
Tamaki 2016; Tursi 2010; Vejdani 2017), and/or steroid therapy
(Matthes 2010; Miele 2009).
Two studies administered their probiotic therapy rectally (Matthes
2010; Oliva 2011), whilst the rest did so orally.
Outcomes
• Remission was reported in 12 of the 14 studies (Kato 2004; Liu
2014; Matthes 2010; Miele 2009; Oliva 2011; Rembacken 1999;
Sanchez-Morales 2019; Solovyeva 2014; Sood 2009; Tamaki
2016; Tursi 2010; Vejdani 2017). Of the 12 studies reporting
on remission, Solovyeva 2014 did not provide a definition
of remission, Liu 2014 assessed remission based on the
Sunderland disease activity index, and the remaining studies
reported on clinical remission.
• Withdrawals due to adverse events were reported in one study
(Sood 2009).
• Serious adverse events were reported in eight studies (Kato
2004; Liu 2014; Matthes 2010; Miele 2009; Oliva 2011; Sood 2009;
Tamaki 2016; Tursi 2010).
• Minor adverse events were reported in nine studies (Kato 2004;
Liu 2014; Matthes 2010; Miele 2009; Sood 2009; Tamaki 2016;
Tursi 2010; Vejdani 2017; Zhang 2018a).
• Time to remission was reported in three studies (Matthes 2010;
Rembacken 1999; Vejdani 2017).
• Disease improvement was reported as improvement in clinical
(Kato 2004; Sanchez-Morales 2019), endoscopic (Tursi 2010),
and histological scores (Sanchez-Morales 2019).
• Histology scores were reported in five studies (Kato 2004;
Matthes 2010; Miele 2009; Oliva 2011; Sanchez-Morales 2019).
• Biochemical scores were reported in two studies (Oliva 2011;
Zhang 2018a).
• Steroid withdrawal, need for additional therapy, progression
to therapy, clinical scores and quality of life scores were not
reported in any of the studies.
Data on the above outcomes were collected and presented in Table
1.
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Funding and declaration of interest
Funding was not stated for seven studies (Kato 2004; Li 2013;
Matthes 2010; Sanchez-Morales 2019; Solovyeva 2014; Vejdani
2017; Zhang 2018a). Two studies stated that they received no
external sources of funding (Miele 2009; Oliva 2011). Two studies
were funded by pharmaceutical industries (Sood 2009; Tursi 2010),
one study by an independent foundation (Tamaki 2016), one study
by a charity (Rembacken 1999), and one study was funded by
several government bodies (Liu 2014).
Seven studies declared no conflicts of interest (Miele 2009;
Rembacken 1999; Sanchez-Morales 2019; Sood 2009; Tamaki 2016;
Tursi 2010; Vejdani 2017). The other seven studies did not report
on conflicts of interest (Kato 2004; Li 2013; Liu 2014; Matthes 2010;
Oliva 2011; Solovyeva 2014; Zhang 2018a).
Excluded studies
Eleven studies failed to meet the inclusion criteria for the following
reasons.
• Full text article could not be found (Bataga 2015).
• Induction and maintenance data presented together (Fujimori
2009).
• Crohn's disease and ulcerative colitis data presented together
(Ballini 2019; IRCT20120415009475N5).
• Commentary piece (Turcotte 2011).
• Cross-over study that presented induction and maintenance
results together (Krag 2013).
• Participants had inactive disease (Bjarnason 2019).
• Outcomes did not include inducing remission (Ishikawa 2003).
• Not randomised (Santana 2010).
• InsuKicient information on study details and no response from
authors when contacted (NCT00895336; NCT00374725).
Risk of bias in included studies
The studies were either at high or unclear risk of bias. The risk of
bias for the studies is summarised in Figure 2 and Figure 3. Further
details are available in the Characteristics of included studies table.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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All of the included studies described their studies as random with
regards to allocation of participants to intervention or control
groups. The method of randomisation was adequately described
in 10 studies (Kato 2004; Li 2013; Liu 2014; Matthes 2010; Miele
2009; Oliva 2011; Rembacken 1999; Sood 2009; Tursi 2010; Vejdani
2017). The remaining studies did not mention their methods of
randomisation; we contacted the authors for clarification, but
received no response (Sanchez-Morales 2019; Solovyeva 2014;
Zhang 2018a). There was also insuKicient information on how the
randomisation list was generated in Tamaki 2016.
Allocation sequence concealment
We judged this as low risk of bias for three studies (Matthes
2010; Rembacken 1999; Sood 2009). These studies described the
use of central allocation (Rembacken 1999), opaque, sealed and
numbered envelopes (Sood 2009), and identical interventions
with specific participant numbers being used to mark delivery
containers (Matthes 2010).
We judged risk of bias as unclear for 11 studies (Kato 2004; Li 2013;
Liu 2014; Miele 2009; Oliva 2011; Sanchez-Morales 2019; Solovyeva
2014; Tamaki 2016; Tursi 2010; Vejdani 2017; Zhang 2018a).
Blinding
Eight studies were described as double-blinded (Matthes 2010;
Miele 2009; Rembacken 1999; Sanchez-Morales 2019; Sood 2009;
Tamaki 2016; Tursi 2010; Vejdani 2017). However, we only judged
two of the 11 studies as low risk for both performance and
detection bias (Kato 2004; Miele 2009). We judged six studies as
low risk for performance bias (Kato 2004; Matthes 2010; Miele 2009;
Tamaki 2016; Tursi 2010; Vejdani 2017), five as unclear, due to
insuKicient detail (Liu 2014; Oliva 2011; Rembacken 1999; Sood
2009; Zhang 2018a), and three studies as high risk due to the intake
of medication for the probiotic and control group being diKerent (Li
2013; Sanchez-Morales 2019; Solovyeva 2014).
For detection bias, we judged 11 studies as unclear (Liu 2014;
Matthes 2010; Oliva 2011; Rembacken 1999; Sanchez-Morales 2019;
Solovyeva 2014; Sood 2009; Tamaki 2016; Tursi 2010; Vejdani 2017;
Zhang 2018a).
Incomplete outcome data
Six studies were at low risk of bias for reporting data for all
participants (Kato 2004; Matthes 2010; Miele 2009; Sanchez-Morales
2019; Tamaki 2016; Tursi 2010). Four studies were unclear (Liu 2014;
Rembacken 1999; Solovyeva 2014; Zhang 2018a). Four studies were
at high risk of bias due to high attrition rates (Oliva 2011; Sood
2009; Vejdani 2017), and non-reporting of outcome data for all
participants in one study group (Li 2013).
Selective reporting
Trial registration was available for one study (Sood 2009), which
failed to report on all prespecified outcomes. We judged four
additional studies as high risk of bias for mentioning non-
significant results without reporting outcome data (Kato 2004;
Matthes 2010; Tamaki 2016), and measuring outcomes without
reporting them (Vejdani 2017).
We judged seven studies as low risk of bias. Six studies did not have
a trial registration, but all expected outcomes were reported (Liu
2014; Miele 2009; Oliva 2011; Rembacken 1999; Sanchez-Morales
2019; Tursi 2010). Two studies were unclear due to insuKicient
information (Li 2013; Solovyeva 2014).
Other potential sources of bias
We judged 10 studies as low of bias (Kato 2004; Liu 2014; Matthes
2010; Miele 2009; Oliva 2011; Solovyeva 2014; Sood 2009; Tamaki
2016; Tursi 2010; Vejdani 2017). We judged two studies as high risk
of bias due to participants being classified according to disease
severity and being given specific concomitant treatments, which
put randomisation into question (Rembacken 1999), and imbalance
in important baseline characteristics (Sanchez-Morales 2019). We
judged two studies as unclear, as no clear statement was made that
the participants were equally matched in Li 2013, and Zhang 2018a
failed to provide suKicient information for a judgement to be made.
E<ects of interventions
See: Summary of findings for the main comparison Probiotics
compared to placebo for induction of remission in ulcerative colitis;
Summary of findings 2 Probiotics compared to 5-aminosalicylic
acid (5-ASA) (mesalazine) for induction of remission in ulcerative
colitis; Summary of findings 3 Probiotics plus 5-aminosalicylic
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acid (5-ASA) (mesalazine) compared to 5-aminosalicylic acid (5-
ASA) (mesalazine) for induction of remission in ulcerative colitis
Probiotics versus placebo
Ten studies compared probiotics with placebo (Kato 2004; Li 2013;
Matthes 2010; Miele 2009; Oliva 2011; Sanchez-Morales 2019; Sood
2009; Tamaki 2016; Tursi 2010; Vejdani 2017). See Summary of
findings for the main comparison.
Primary outcomes
Clinical remission
There is low-certainty evidence that probiotics may improve
induction of clinical remission, when compared with placebo (risk
ratio (RR) 1.73, 95% confidence interval (CI) 1.19 to 2.54; 9 studies,
594 participants; I2 = 55%; random-eKects model; Analysis 1.1,
number needed to treat for an additional beneficial outcome of 5).
We downgraded the evidence for high risk of bias in the majority of
studies and imprecision due to sparse data. We did not downgrade
for inconsistency as the eKect estimates appeared to be fairly
consistent across studies and we judged heterogeneity to be as a
result of diKerences in probiotic preparations.
Sensitivity analysis
We analysed the data using a fixed-eKect model and obtained
similar, but more precise results (RR 1.78, 95% CI 1.41 to 2.25; 9
studies, 560 participants; I2 = 55%; low-certainty evidence). Further
exclusion of the studies at high risk of bias from the main analysis
found that it is uncertain whether probiotics lead to a diKerence
in clinical remission (RR 2.04, 95% CI 0.83 to 4.96; 2 studies, 71
participants; I2 = 72%; very low-certainty evidence).
Subgroup analysis
We carried out the subgroup analysis to investigate whether age is
an eKect modifier. The analysis found probiotics to be beneficial in
both adults (RR 1.49, 95% CI 1.07 to 2.08; 525 participants, 7 studies;
I2 = 43%; very low-certainty evidence, number needed to treat
for an additional beneficial outcome of 7) and children (RR 3.83,
95% 1.69 to 8.66; 2 studies, 69 participants; I2 = 0%; low-certainty
evidence, number needed to treat for an additional beneficial
outcome of 3), with a slightly greater eKect in the paediatric
population (test for subgroup diKerences: Chi2 = 4.42, P = 0.04, I2
= 77.4%) (Analysis 1.2, Figure 4). These results are similar to those
obtained in the main analysis, but should be interpreted cautiously,
given the small number of studies analysed.
 
Figure 4.   Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.2 Clinical remission: subgroup analysis
by age.
 
We also assessed whether clinical remission was aKected by the
number of strains in probiotics. There was neither a qualitative nor
quantitative diKerence between probiotics with multiple strains
(RR 2.02, 95% CI 1.31 to 3.12; 5 studies, 374 participants; I2 = 32%)
and those with single strains (RR 1.44, 95% CI 0.79 to 2.63; 4 studies,
220 participants; I2 = 57%) (Analysis 1.3). Subgroup analyses are
rarely informative when there are sparse data, therefore, these
results should be interpreted with caution.
Histological remission
It is unclear whether probiotics lead to a diKerence in histological
remission when compared with placebo due to very low-certainty
evidence (RR 2.50, 95% CI 0.56 to 11.16; 1 study, 34 participants). We
downgraded the evidence once due to high risk of bias and twice
for very serious imprecision (Analysis 1.4).
Probiotics for induction of remission in ulcerative colitis (Review)









Cochrane Database of Systematic Reviews
Secondary outcomes
Disease improvement
There was improved clinical disease severity when probiotics were
compared with placebo (RR 2.29, 95% CI 1.13 to 4.63; 2 studies,
54 participants; low-certainty evidence). We downgraded the
evidence once for risk of bias and once due to serious imprecision.
There is moderate-certainty evidence showing that probiotics
probably reduce disease severity assessed by endoscopic scores
when compared with placebo (RR 1.45, 95% CI 1.03 to 2.05; 1
study, 144 participants). We downgraded the evidence once due
to imprecision due to the small number of participants. It is
uncertain whether probiotics result in a diKerence in histological
improvement when compared with placebo because the evidence
is of very low certainty (RR 2.00, 95% CI 1.09 to 3.68; 1 study, 34
participants) (Analysis 1.5).
Steroid withdrawal
This outcome was not reported.
Clinical activity scores
Clinical activity scores were reported in one study (Miele 2009). In
the probiotics and placebo groups, the mean was 10.9 versus 11.1.
However, measures of variance were not reported.
Histology scores
Histology scores were reported in three studies (Kato 2004; Miele
2009; Oliva 2011). MDs ranged between -3.38 and -0.95 in the three
studies (79 participants). We did not pool data due to considerable
heterogeneity (I2 = 90%; Analysis 1.7). However, two studies with
suKicient data consistently showed lower histology scores in the
probiotics group (low-certainty evidence).
Biochemical markers of inflammation
Kato 2004 measured C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR), however, no data were reported. Other
markers of inflammation were reported in Oliva 2011. We manually
extracted the data on tumour necrosis factor (TNF)TNF - α,
interleukin 10 (IL-10), interleukin 1 beta (IL-1β) and interleukin 8
(IL-8) from graphs, as shown in Analysis 1.8.
Need for additional therapy
This outcome was not reported.
Progression to surgery
This outcome was not reported.
Symptomatic severity (stool frequency, abdominal pain)
This outcome was reported in five studies in diKerent ways (Matthes
2010; Miele 2009, Sood 2009; Tamaki 2016; Tursi 2010).
• Matthes 2010 measured defecation frequency, occurrence of
rectal bleeding, general disease activity, self-assessments by
participants and investigators, as well as global assessment of
health. However, data were not shown.
• Miele 2009 reported on physicians global assessment of disease
and the proportion with moderate (42% versus 33%) and
severe (58% versus 67%) activity of disease were reported. The
mean clinical activity scores were 10.9 (14 participants) versus
11.11 (15 participants) in the probiotics and placebo groups,
respectively. Measures of variance were not reported, therefore,
we could not analyse this data (Analysis 1.6).
• Sood 2009 reported a physician global assessment score of
0.68 (probiotics) versus 1.1 (placebo); stool frequency score 1.04
(probiotics) versus 1.66 (placebo); and rectal bleeding score 0.48
(probiotics) versus 1.01 (placebo).
• Tamaki 2016 measured rectal bleeding (figures reported in text
and graph were inconsistent, therefore, not presented); stool
frequency (data not shown); and physicians global score (data
not shown).
• Tursi 2010 reported on the proportion of participants with
improvement in stool frequency (48% for probiotics versus 38%
for placebo); improvement of physician rating of disease activity
(43% for probiotics versus 25% for placebo); and reduction of
rectal bleeding (55% for probiotics versus 31% for placebo).
Quality of life scores
Matthes 2010 measured quality of life (using a visual analogue scale
(VAS)), however, data were not shown.
Time to remission/improvement
Time to remission was reported in two studies (Matthes 2010;
Vejdani 2017). Matthes 2010 stated that "time to remission was
shorter in the 40 mL and 20 mL Escherichia coli Nissle (EcN) groups
than in the 10 mL EcN and placebo groups. Vejdani 2017 reported
median time to remission of 23 days and 25 days with probiotics
and placebo, respectively. Data were not suKiciently reported in
either study, to allow further analysis.
Minor adverse events
It is uncertain whether probiotics lead to a diKerence in the
occurrence of minor adverse events when compared with placebo
(RR 1.04, 95% CI 0.42 to 2.59; I2 = 69%; 7 studies, 520 participants;
random-eKects model; Analysis 1.9). We downgraded the evidence
for high risk of bias, inconsistency (I2 = 69%), and imprecision, as
the CI included a risk of benefit and harm.
Serious adverse events
It is uncertain whether probiotics lead to a diKerence in the
occurrence of serious adverse events when compared with placebo
(RR 0.09, CI 0.01 to 1.66; 7 studies, 526 participants; very low-
certainty evidence; Analysis 1.10, Figure 5). We downgraded the
evidence for high risk of bias and imprecision, as the CI included a
risk of benefit and harm.
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Figure 5.   Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.10 Serious adverse events.
 
Withdrawal due to adverse events
There is low-certainty evidence showing that probiotics make little
or no diKerence in the number of people needing to withdraw due
to adverse events when compared with placebo (RR 0.85, CI 0.42
to 1.72; 4 studies, 401 participants; low-certainty evidence; Analysis
1.11). We downgraded the evidence for imprecision due to wide CIs
which includes a risk of benefit and harm.
Probiotics versus 5-aminosalicylic acid (5-ASA) (mesalazine)
Two studies compared probiotics with 5-ASA (Li 2013; Rembacken
1999). See Summary of findings 2.
Primary outcome
Clinical remission
It is uncertain whether probiotics lead to a diKerence in the number
of people who attain remission when compared with 5-ASA (RR
0.92, 95% CI 0.73 to 1.16; 1 study, 116 participants; low-certainty
evidence; Analysis 2.1). We downgraded the evidence for high risk




This outcome was not reported.
Steroid withdrawal
This outcome was not reported.
Clinical activity scores
There is low-certainty evidence that probiotics may slightly reduce
clinical activity scores compared to 5-ASA (mean diKerence (MD)
-2.07, 95% CI -3.22 to -0.92; 1 study, 76 participants; Analysis 2.2).
Our confidence in the result is limited as the evidence is from a small
study which reported no information to allow us to judge risk of bias
in any of the domains.
Histology scores
This outcome was not reported.
Biochemical markers of inflammation
One study (76 participants) reported on the eKect of probiotics
compared to 5-ASA on serum IL-4 (MD 2.53, 95% CI 0.47 to 4.59),
serum IL-8 (MD -66.10, 95% CI -71.63 to -60.57) and high-sensitivity
C-reactive protein (hs-CRP) (MD -3.03, 95% CI -3.45 to -2.61). Our
confidence in the result is limited as the evidence is from a small
study which reported no information to allow us to judge risk of bias
in any of the domains (Analysis 2.3).
Need for additional therapy
This outcome was not reported.
Progression to surgery
This outcome was not reported.
Symptomatic severity (stool frequency, abdominal pain)
This outcome was not reported.
Quality of life scores
This outcome was not reported.
Time to remission/improvement
There is low-certainty evidence that in any given number of people
receiving therapy for the induction of remission, 50% may achieve
remission in less time with probiotics than placebo (37 days versus
42 days; 116 participants; reported P = 0.0092). We downgraded for
high risk of bias and imprecision due to small sample size from a
single study.
Minor adverse events
It is uncertain whether probiotics lead to a diKerence in minor
adverse events because the certainty of the evidence is very low
(RR 1.23, 95% CI 0.56 to 2.70; 2 studies, 192 participants; very low-
certainty evidence; Analysis 2.4). We downgraded the evidence due
to high risk of bias and imprecision due to small sample size and
sparse data.
Serious adverse events
It is uncertain whether probiotics lead to a diKerence in serious
adverse events because the certainty of the evidence is very low
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(RR 0.21, 95% CI 0.01 to 4.22; 1 study, 116 participants; very low-
certainty evidence; Analysis 2.5). We downgraded the evidence due
to high risk of bias and imprecision due to small sample size and
sparse data from a single study.
Withdrawal due to adverse events
It is uncertain whether probiotics lead to a diKerence in withdrawals
due to adverse events because the certainty of the evidence is very
low (RR 0.21, 95% CI 0.01 to 4.22; 1 study, 116 participants; very low-
certainty evidence; Analysis 2.6). We downgraded the evidence due
to high risk of bias and imprecision due to small sample size and
sparse data from a single study.
Probiotics plus 5-aminosalicylic acid (5-ASA) (mesalazine)
versus 5-ASA (mesalazine)
Three studies compared probiotics plus 5-ASA to 5-ASA (Li 2013; Liu
2014; Solovyeva 2014). See Summary of findings 3.
Primary outcome
Remission (based on Sunderland disease activity scores)
There is low-certainty evidence that probiotics, when coupled with
5-ASA, may slightly increase the number of people who attain
remission when compared with 5-ASA alone (RR 1.22, CI 1.01 to
1.47; 1 study, 84 participants; low-certainty evidence; Analysis 3.1).
We downgraded the evidence for unclear risk of bias in most of the
domains and imprecision due to small sample size of a single study.
Secondary outcomes
Symptomatic severity (stool frequency, abdominal pain)
Clinical activity scores were reported in Solovyeva 2014. However,
the number of participants randomised to each group was not
stated, therefore we were unable to analyse the data. Mean scores
were 4.5 (SD 1.5) versus 6.7 (SD 1.3) in 47 participants.
None of the other secondary outcomes were reported.
D I S C U S S I O N
Summary of main results
This review included 14 parallel group randomised controlled
trials (RCTs) assessing the eKectiveness of probiotics in inducing
remission in ulcerative colitis. All the studies except Li 2013
provided suKicient data for inclusion in a meta-analysis. The
comparisons assessed by the studies were probiotics versus
placebo, probiotics versus 5-aminosalicylic acid (5-ASA) and
probiotics plus 5-ASA versus 5-ASA alone. See Summary of findings
for the main comparison; Summary of findings 2; Summary of
findings 3.
We analysed and summarised data from 865 participants.
• Probiotics may improve induction of clinical remission when
compared with placebo (low-certainty evidence).
• There may be little or no diKerence in the induction of remission
with probiotics when compared with 5-ASA (low-certainty
evidence).
• There is limited evidence to show that probiotics plus 5-ASA
may slightly improve the induction of remission (based on the
Sunderland disease activity index) when compared with 5-ASA
alone (low-certainty evidence).
• Probiotics probably reduce disease severity, based on
endoscopic scores, when compared with placebo (moderate-
certainty evidence).
• Probiotics may improve clinical disease severity when
compared with placebo (low-certainty evidence).
• The most common minor adverse events were abdominal
bloating and discomfort (very low-certainty evidence).
• All seven studies comparing probiotics with placebo, which
recorded serious adverse events, reported no events occurring
with probiotics (very low-certainty evidence).
• Probiotics may make little or no diKerence in the number
of people withdrawing from treatment due to adverse events
compared to placebo (low-certainty evidence).
• There were insuKicient data on biochemical markers of
inflammation, time to remission, symptomatic severity,
histology scores and clinical activity scores.
• None of the studies reported on steroid withdrawal, need for
additional therapy, or quality of life scores.
Overall completeness and applicability of evidence
The range of studies analysed in this review led to heterogeneity
in all aspects. This produces limitations when trying to apply
a guide to decision making. When shared decision making is
made by clinicians and practitioners, they need not only facts,
but pragmatic and useful ways of applying those facts to their
individual patients. The clinical heterogeneity in almost all areas
(e.g. methods of identifying disease activity as baseline, methods of
defining remission, improvement, adverse events, the huge range
of individual patient demographics, the routes of administration,
and specific strains of probiotics) really limits the way in which
these findings can be confidently applied to individual patients.
Updating this review aTer almost 10 years has highlighted the
growing body of evidence, but it is disappointing that these barriers
to the utility of the evidence base exists. Indeed, this raises the
question, as to why strategically over the years, studies have not
looked to build sequentially on one another. When synthesising
studies in this review, the field appears to comprise of disparate
works produced in isolation of the wider clinical research field.
There is insuKicient information to fully describe the relevance
of the evidence due to poor reporting across the studies. None
of the studies were restrictive in terms of gender or age, there
were some restrictions on the severity of ulcerative colitis, as no
study chose to include participants with severe disease. Apart from
two studies (Miele 2009; Oliva 2011), all studies recruited adults.
A formal subgroup analysis looking at age as an eKect modifier,
found no qualitative diKerence in remission between the adult and
paediatric population. However, there is a quantitative diKerence
between adults and children. When we further analysed the data by
number of strains, there was neither a qualitative nor quantitative
diKerence. Given the insuKicient data these findings should be
interpreted with caution. We intend to explore these subgroups in
future updates when more trials become available.
Follow-up ranged from two weeks to 52 weeks. Eight out of
the 12 studies used concomitant treatment, and for a further
two studies it was not clear whether concomitant treatment was
allowed. This causes uncertainty in terms of attributing treatment
eKects or adverse events to the concomitant treatment or the
study intervention itself. Rembacken 1999 also reported on adverse
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outcomes, however it presented its data from induction and
maintenance together, which made it unclear to analyse, it also
used gentamicin for one week prior to the start of the study, so it is
diKicult to assess whether the adverse events were caused by the
intervention or prior treatment.
Six out of the 12 studies had probiotics that were directly supplied
by the pharmaceutical manufacturer. For the other six studies, it
was possible to search for an online retailer who sold the probiotic,
however the studies themselves did not identify the source of their
intervention. The probiotics used were both yogurt drinks and food
supplements.
Time to remission was reported in two studies, however one study
reported this as mean number of days, and the second study
provided a graph, which made it unclear to derive statistical data
from.
Certainty of the evidence
The certainty of the evidence ranged from moderate to very low.
However, the moderate graded evidence only included one study.
The main reasons for low grades of evidence were imprecision,
due to small numbers, or high/unclear risk of bias. The issue
with risk of bias is particularly pervasive in the field, and is a
largely avoidable barrier impacting the certainty of the evidence
in this review. Most of the studies failed to describe the blinding
of outcome assessors adequately and also failed to adequally
report on allocation concealment. Two studies mentioned that
histopathologists were blinded, but failed to explicitly mention if
other outcome assessors were also blinded. Two studies had to be
translated into English, and one study was an abstract, which was
unclear for most domains in risk of bias. Whilst it is possible that
there was genuine bias within the studies, most of these sources
would easily be managed through following international guidance
on trial design. Similarly, poor reporting should also be easily
addressed through peer review, ensuring these are addressed
prior to publication. As it stands, we downgraded every outcome
comparison due to the risk of bias.
The study samples ranged from 20 to 147 participants; these small
numbers resulted in wide confidence intervals (CIs). Indeed, whilst
some studies produced power calculations, the assumptions they
used are very much out of keeping with the size of treatment
eKects that are seen across Cochrane Inflammatory Bowel Disease
portfolios of reviews, and as such the question as to whether these
studies were underpowered remains. This is once again a pervasive
problem across the field.
Due to moderate and substantial heterogeneity, we downgraded
for inconsistency. These inconsistencies may be explained by
significant diKerences in clinical characteristics across the studies,
however, there were insuKicient data to investigate further.
There was no indirectness, as the included studies all addressed the
objectives of the review, and were within the scope. The number of
studies included in the meta-analysis was insuKicient to assess for
publication bias (less than 10).
Potential biases in the review process
Some studies reported outcomes as proportions; in order to include
the data in the analysis, we calculated the number of events. We
were able to minimise errors by having two independent review
authors extract the data. The review authors contacted study
authors for additional information and clarifications, however
some authors failed to reply. We aim to include any data which
become available in future updates.
We had less than the recommended number of studies required to
carry out a subgroup analysis, but still analysed the results by age to
assess whether it was an eKect modifier. We are aware that this can
lead to type I error and have advised that the results be interpreted
cautiously.
One study is only available as an abstract and a second study did
not provide suKicient data. We did not explore the impact of these
studies in a sensitivity analysis.
We are aware of the possible impact of industry funding on the
validity of trial results. Funding form manufacturing companies
or any conflicts of interests that were declared were noted in the
relevant studies, but in many studies these details were simply
omitted. We did not take these into account in carrying out the
'Risk of bias' assessment of the studies or GRADE assessment of the
evidence.
Agreements and disagreements with other studies or
reviews
There is currently no other known evidence-based guidance
or systemic review around the use of probiotics for the
induction of remission in ulcerative colitis, except the previous
version of the review (Mallon 2007). The European Crohn's and
Colitis Organisation (ECCO) and European Society of Paediatric
Gastroenterology, Hepatology and Nutrition (ESPHGAN) guideline
recommends the use of probiotics as add-on therapy for adults and
children with mild ulcerative colitis (Turner 2018), but not as a first-
line therapy, despite the findings and relatively low number needed
to treat for an additional beneficial outcome (NNTB). Our review
found evidence from one study supporting this recommendation,
however, we consider it insuKicient to draw conclusions on the use
of probiotics as add-on therapy. The current NICE guidelines do not
recommend the use of probiotics in the conservative management
of ulcerative colitis (NICE 2013). Mallon 2007 found that as a
stand alone or combined therapy, probiotics led to no diKerences
in remission rates. This was based on scant evidence from four
studies. The results of the current review show that probiotics may
improve remission in comparison with placebo. When combined
with 5-ASA it may slightly improve remission than 5-ASA alone.
Even though this is based on low-certainty evidence, it changes the
conclusion of the previous review, and in particular has specific
implications for future research (see below).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is low-certainty evidence that probiotics may induce clinical
remission in active ulcerative colitis compared to placebo, with
a number needed to treat for an additional beneficial outcome
of 5. The certainty of the evidence means that the true eKect
may be substantially diKerent from the estimate of the eKect, and
future research may therefore change this finding. This is due to
the flaws in reporting of studies and the inclusion of inadequate
numbers of study participants. There may be little or no diKerence
in the eKects of probiotics alone compared with 5-aminosalicylic
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acid (5-ASA), due to very low-certainty evidence. There is limited
evidence from a single study which failed to provide a definition
of remission, that probiotics may confer a small added benefit
in inducing remission when combined with 5-ASA, over 5-ASA
alone. There is no clear diKerence in withdrawals due to adverse
events between probiotics and placebo. This is also based on low-
certainty evidence. Minor and serious adverse events were poorly
reported (very low-certainty evidence). The applicability of the
evidence in clinical practice is limited due to the heterogenous
studies and this is reflected in the low to very low rating in certainty
of the evidence. Commonly reported minor adverse events were
abdominal bloating and discomfort. None of the studies reported
any serious adverse events with probiotics.
Implications for research
This review highlights the need for further research in this area that
targets relevant clinical questions, uses appropriate and improved
trial procedures, and reports in a manner that will allow future
integration with this current evidence base to produce the clearer
answers clinicians and patients require. There is only one trial
ongoing.
In terms of trial quality, first the conception of trials must be
considered. Eight studies had compared probiotics to placebo,
which is not representative of current clinical practice, where
patients will be on standard therapy to aid being induced.
Therefore, it would be more suited for studies to compare
probiotics plus standard care versus standard care alone, or indeed
three-armed trials.
The question of sample size is also a major concern, as stated
above. The eKect sizes reported in this review should form an
appropriate source of data for future power calculations, and allow
suitable sample sizes to be recruited.
As there is some limited evidence from a single trial of probiotics
added to 5-ASA therapy conferring a benefit when compared
to 5-ASA alone, this may form a natural foundation for future
investigation.
The length of the studies were variable, and the time to relapse was
not reported in most studies, and again these are key pragmatic
questions that will support decision making from such trial data.
Future studies should also consider whether they will also measure
the rates of longer-term relapse aTer initial induction. However, if
they choose to do this, suitably lengthy follow-up times must be
used.
Adverse events were capriciously reported amongst the studies,
which was a concern with our service user author. Given that the
class of agent can be directly available to patients, it is important
for their safety and autonomy that adverse events are graded as
minor and severe, and defined in the study to aid future systematic
reviews, and allow patients to make informed decisions if they
choose to obtain the agent independently.
Studies should also consider the eKects of diKerent probiotics,
diKerent dosing regimens and specific patient subgroups, for
example patients with severe disease who may benefit from
probiotic treatment or children.
Service user involvement in the review process has brought to the
forefront key issues, which are important to patients and need to be
taken into account in future research. As probiotics can be available
both as prescribed medical agents and food supplements direct
to patients, both cohorts are recognised in the studies included.
Future research may wish to explicitly state the local status of
studied products as this has implications for patients in terms
of availability and autonomy in considering the potential role of
probiotics, in addition to eKicacy and safety concerns.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomised placebo-controlled trial
Setting: multicentre, Tokyo, Japan, hospital and outpatients
Study period: September 2001 to March 2003
Participants Inclusion criteria: active mild to moderate UC (8 mild and 12 moderate) according to the criteria of
Truelove 1955, no prednisolone for at least 1 year before starting the trial
Exclusion criteria: topical or systemic steroids or antibiotics within the preceding 4 weeks
Age (mean): 30.2 (probiotics) 33.7 (placebo)
Sex (M/F): 5/5 (probiotic), 5/5 (placebo)
Site of disease: proctitis 3, leT colon involved 2, proctosigmoiditis 0, total colitis/sub 5 (probiotics)
proctitis 4, leT colon involved 3, proctosigmoiditis 0, total colitis/sub 3 (Placebo)
Use of concurrent medication: salazosulfapyridine, aminosalicylate
Treatment before study: not stated
Number randomised: 10 (probiotic), 10 (placebo)
Number analysed: 10 (probiotic), 9 (placebo)
Postrandomisation exclusion: 1- worsening symptoms 2 days after trial starting
Interventions • Probiotic bifidobacteria-fermented milk (Bifidobacterium breve (B breve) + Bifidobacterium bifidum (B
bifidum) + Lactobacillus acidophilus (L acidophilus) YIT 0168) plus standard therapy (2.25 g to 3 g 5-
ASA or 3 g to 4 g SASP daily)
• for 12 weeks
• Placebo plus concurrent therapy
Outcomes • Proportion achieving remission (remission defined as absence of rectal bleeding, a rectal mucosa
without erythema, granularity, or friability and normal or near-normal sigmoidoscopic findings




Notes Funding- not stated
Conflicts of interests- not stated
Kato 2004 
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Contacted author 29 March 2018 - no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: a random number table was used. Quote: "The 20 subjects were
then randomly assigned to either the group (n = 10) receiving BFM supplemen-
tation (BFM group), or the control group (n = 10) receiving a placebo (placebo
group), using a random number table"
Allocation concealment
(selection bias)
Unclear risk Quote: "Delivered to the homes of BFM group members....the BFM placebo
product, was delivered to the homes of placebo group members." Comment:






Low risk Placebo and intervention were similar in taste and appearance. Quote: "There
was no difference in either taste or appearance between the two prepara-
tions."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The endoscopic activity index score was first determined at the time of
the procedure, based on a review of endoscopic photographs taken by experi-
enced endoscopists, blinded to the mode of treatment[…]Histopathological
inflammatory activity was assessed before and 12 weeks after starting treat-
ment with at least four biopsy specimens taken from actively inflamed mu-
cosa, including a rectal biopsy, with the most severe inflammation being docu-




Low risk All reported
No significant difference in attrition across study group
Selective reporting (re-
porting bias)
High risk Quote: "There were no significant changes in routine biochemical data or urine
analyses after treatment [...]. There was a slight improvement in inflammatory
reaction [...], but it did not reach statistical significance"
Comment: trial registration not available and non-significant results were
mentioned, but not adequately reported.
Other bias Low risk Comment: participants used in both groups were comparable. Quote: "No sig-
nificant differences were found between the two groups in age, gender, extent
of disease, disease severity, disease duration or treatment".





Setting: single centre, China
Study period: May 2007 to June 2010
Participants Inclusion criteria: diagnosis of UC, chronic recurrent or active patients
Exclusion criteria: fulminant UC, infectious enteritis, ischaemic enteritis, radioactive enteritis, any UC
with colorectal cancer
Li 2013 
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Age (mean SD): 39 +/- 6 (probiotic) 32 +/- 8 (combination) 36 +/-7 (olsalazine)
Sex (M/F): 8/12 (probiotic), 11/9 (combination), 12/8 (olsalazine)
Site of disease: not stated
Use of concurrent medication: not clearly stated
Treatment before study: not stated
Number randomised: 20 (probiotic), 20 (combination), 20 (olsalazine), 20 (control)
Number analysed: 20 (probiotic), 20 (combination), 20 (olsalazine)
Postrandomisation exclusion: 0
Interventions • Golden bifid (3 strains Bifidobacterium (B bifidum), Lactobacillus bulgaricus (L bulgaricus), streptococ-
cus thermophilus (L thermophilus)), 2 g orally, 2 times/day
• Changmei (olsalazine capsules, 1 g orally, 3 times/day)
• Combination group
Outcomes • Increase in clinical symptom score
• Increase in endoscopic score
• Increase in histopathological score
Notes Translated article from simple Chinese to English
Funding - not stated
Conflicts of interest - not stated
Contacted author 30 August 2018 - no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Table of random numbers used
Allocation concealment
(selection bias)





High risk Different intake of medication
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk Trial registration not available. Insufficent information to determine whether
all prespecified outcomes were reported
Other bias Unclear risk Not stated if participants matched across all groups
Li 2013  (Continued)
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Methods Randomised, two intervention arms
Setting: China, suggests single centre provincial hospital
Study period: September 2010 to September 2012
Participants Inclusion criteria: unclear - suggests 25-62 age, (Sutherland disease activity index was used)
Exclusion criteria: not clearly stated
Age (mean SD): 42.8 (4.8) (probiotics + mesalazine) 40.2 (5.2) (mesalazine)
Sex (M/F): 20/22 (probiotic + mesalazine, 19/23 (mesalazine)
Site of disease: not clearly stated
Use of concurrent medication: not clearly stated
Treatment before study: not stated
Number randomised: 42 (probiotic + mesalazine), 42 (mesalazine)
Number analysed: 42 (probiotic + mesalazine), 42 (mesalazine)
Postrandomisation exclusion: 0
Interventions 3 strains of Bifidobacterium plus mesalazine, made by Dr Falk
Control group: mesalazine
Method: oral, 1 g 3 times/day or 2 g 2 times/day
Follow-up 8 weeks
Outcomes • Number inducing remission
• Adverse events
• Withdrawals
Notes Mandarin - translated
Combined treatment, DIA goes from 5.36 (+/- 1.01) to 1.85 (+/- 1.40) and control group, 5.42 (+/-1.53) to
3.60 (+/-1.22) P (0.043)
Funding - Natural National Science Foundation of China and several other national Chinese funding
bodies (All public)
Conflicts of interest - not stated
Contacted author on 16 January 2018
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer method
Allocation concealment
(selection bias)
Unclear risk Contacted author, but no response
Liu 2014 
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Unclear risk No mention in translated text
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk No flow diagram
Selective reporting (re-
porting bias)
Low risk All primary outcomes reported
Other bias Low risk Both groups similar




Methods Explorative, randomised, double-blind, placebo-controlled, parallel group, multicentre, phase 2, dose-
finding study
Setting: multicentre, German hospital and community
Study period: November 1999 to June 2002
Participants Inclusion criteria: 18 to 70 years, DAI according to Sutherland disease activity index 4-9, proctitis with
inflammation beginning at the anus < 15 cm, and proctosigmoiditis with inflammation beginning at the
anus up to the end of the colon sigmoideum (about 25-30cm from anus), two confirmed prior manifes-
tation of disease
Exclusion criteria: other causes of acute proctitis/proctosigmoiditis such as infections, medical drugs,
radiation, ischaemias of affected intestinal segments, and Crohns disease. A history of stool inconti-
nence, perianal fistulae, major colonic surgery, colorectal carcinoma or stenoses. Other severe accom-
panying disease. Participation in other clinical trial either simultaneously or within 30 days, no medica-
tion such as oral EcN within 4 weeks prior to study, rectal treatment with steroids or aminosalicylates
within 2 weeks before the study, immunosuppressants within 90 days before inclusion and antibiotics
or sulphonamides during the study course. Lack of co-operation, inadequate contraception, pregnancy
or breast feeding and obesity.
Age (mean SD): 40.1 +/- 11.7 (probiotics) 47.4 +/- 13.8 (placebo)
Sex (M/F): 37/31 (probiotic), 12/8 (placebo)
Site of disease: not stated
Use of concurrent medication: loperamide drops to improve retention capacity for enemas, and oral
UC maintenance treatment with aminosalicylates or steroids at a constant level for at least two weeks
prior to the study
Treatment before study: not stated
Number randomised: 70 (probiotic), 20 (placebo)
Number analysed: 68 (probiotic), 20 (placebo)
Matthes 2010 
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Postrandomisation exclusion: 2 (probiotic) no intake of medication
Interventions Non-pathogenic Escherichia coli strain Nissle 1917, Argeypharm, Herdecke, Germany 10 to power of 8
micro-organisms per mL
Enema of 40 mL, 20 mL and 10 mL
Placebo: enema devoid of the active substance
Followed up for 2, 4 and 8 weeks
Outcomes • Proportion achieving remission - (remission defined as clinical DAI ≤ 2
• Time to remission
• Endoscopic mucosal healing (DAI = 0)
• Disappearance of histological signs of significant inflammation
Notes Funding - not stated
Declaration of conflicts - not stated
Contacted author 13 April 2018 - no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A random number table was used. Quote: "Using standard predetermined ran-




Low risk Quote: "blinding of the investigator and patient was ensured by the provision






Low risk Placebo controlled trial
Quote: "blinding of the investigator and patient was ensured by the provision
of study medication identical in appearance, with a patient specific randomi-
sation number"
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk Attrition rates were low and balanced across groups
Selective reporting (re-
porting bias)
High risk Trial registration not available, however, the methods section shows that
health related quality of life was measured using a 100 mm VAS. The results of
this outcome were not reported.
Other bias Low risk No apparent differences between baseline characteristics of the two groups
were seen.
Conconimant diseases and therapies were not different between the groups.
Quote: "there were no apparent differences between the study groups at base-
line. Similarly, their case histories were comparable".
Matthes 2010  (Continued)
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Methods Prospective, single centre, placebo-controlled, double-blind, 1-year study
Setting: single centre, Italy, hospital
Study period: not stated
Participants Inclusion criteria: new diagnosis of UC, established on accepted historical, endoscopic, histologic,
and/or radiologic criteria, which needed a steroid therapy to induce the remission of the disease
Exclusion criteria: children who had received therapy inducing remission of UC; Children who re-
quired outpatient antibiotic therapy and/or required surgery for complications related to UC; children
with documented history of allergic reaction to lactobacillus or other probiotic compound or with his-
tory of endocarditis, rheumatic valvular disease, congential cardiac malformations, or cardiac surgery;
and children who had received any other probiotic bacterial supplement within the past 10 days.
Age (mean SD): not stated (probiotics); not stated (placebo)
Sex (M/F): 8/6 (probiotic), 8/7 (placebo)
Site of disease: proctitis 0, leT colon involved 5, proctosigmoiditis 4, total colitis/sub 5 (probiotics)
proctitis 0, leT colon involved 4, proctosigmoiditis 3, total colitis/sub 8 (placebo)
Use of concurrent medication: oral methylprednisolone for 4 weeks, oral mesalamine maintenance
Treatment before study: not stated
Number randomised: 14 (probiotic), 15 (placebo)
Number analysed: 14 (probiotic), 15 (placebo)
Postrandomisation exclusion: none
Interventions 4 strains of Lactobacillus (L Paracasei, L Planatum, L Acidophykus, L Delbrueckii subsp. bulgaricus), 3
strains of Bifidobacterium (B Londum, B Breve, and B infantis), and 1 strain of Streptococcus salivarius
subsp thermophilus. 900 billion viable lyophilised bacteria, weight-based dose
Placebo: 3g of corn starch
Outcomes • Proportion reaching remission (remission defined as sustained drop in LCAI to < 2 after steroid ther-
apy)
• Relapse within 1 year (relapse defined as occurrence or worsening of symptoms, accompanied by an
increase in LCAI > 3, sufficient to require treatment with corticosteroids, azathioprine/immunosup-
pressive agents or surgery)
Notes Funding- states received none
Conflicts of interests - declared none
Contaced author 23 April 2018 - no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation scheme
Allocation concealment
(selection bias)
Unclear risk Randomisation codes kept by one investigator until end of study. However, it
is unclear whether the investigator was involved in the study.
Miele 2009 
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Quote: "Randomization was performed by one blind clinical trial investigator,
who kept the codes until completion of the study. None of the staK or patients





Low risk Intervention agent and placebo were similar. Quote: "Placebo was provided
in identical bags...taste and smell of the active drugs were not readily identifi-
able"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Pathologist who analysed biopsy samples was blinded. Quote: "All histolog-
ic specimens were reviewed under code by a single pathologist experienced





Low risk There was no attrition.
Selective reporting (re-
porting bias)
Low risk Trial registration not found, however authors report on all outcomes.





Methods Prospective randomised, placebo-controlled study
Setting: single centre, Rome, Italy, hospital
Study period: November 2008 to February 2011
Participants Inclusion criteria: confirmed endoscopic and histological diagnosis of ulcerative proctitis/proctosig-
moiditis with mild to moderate disease activity
Exclusion criteria: other causes of active proctitis or proctosigmoiditis such as infections, medical
drugs and CD; furthermore, patients who had received either oral or topical corticosteroids, topical
aminosalicylates, antibiotics during the previous 12 weeks and immunomodulator's during the previ-
ous 20 weeks were excluded from the trial.
Age (mean SD): 13 (probiotics) 12.5 (placebo)
Sex (M/F): 8/6 (probiotic, 9/7(placebo)
Site of disease: proctitis 3, leT colon involved 2, proctosigmoiditis 0, total colitis/sub 5 (probiotics)
proctitis 4, leT colon involved 3, proctosigmoiditis 0, total colitis/sub 3 (placebo)
Use of concurrent medication: oral mesalazine
Treatment before study: chronic administration of oral mesalazine at a dose ranging from 50 mg/kg/
day to 75 mg/kg/day during the last 12 weeks
Number randomised: 20 (probiotic), 20 (placebo)
Number analysed: 16 (probiotic), 15 (placebo)
Postrandomisation exclusion: low compliance 3 (probiotic) 4 (placebo); acute infectious episode 1
(probiotic) 1 (placebo)
Interventions 10 to the power of 10 CFU L reuteri ATCC 55730
Oliva 2011 
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Placebo: not stated
Outcomes • Proportion inducing remission (Final DAI score of < 2.0 points)
• Changes in rectal histology and in the inflammatory cytokine mucosal expression
Notes Funding - declares none
Conflicts of interests - declares none
Contacted author 29 March 2018 - no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated list used. Quote: "Randomisation was performed accord-
ing to a computer-generated list by means of sequentially numbered sealed
envelopes indicating their medication"
Allocation concealment
(selection bias)
Unclear risk The study states that they used sequentially numbered sealed envelopes indi-
cating their medication to conceal from participants, however did not mention





Unclear risk Study referred to as "placebo-controlled". However, further details were not
provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Over 20% attrition rate and ITT analysis not conducted
Selective reporting (re-
porting bias)
Low risk Trial registration not available but all outcomes reported
Other bias Low risk Balance of baseline characteristics across both groups. No other sources of
bias found. Quote: "At baseline, all patients had a moderate active UC and the





Setting: single centre, German Hospital
Study period: not stated
Only used induction data
Participants 57 patients received probiotics, steroids and gentamicin
59 patients received mesalazine, steroids and gentamicin
Inclusion criteria: 18 to 80 years, active UC (> 4 liquid stools for 7 days), erythema on sigmoidoscopy as
well as histological confirmation of active UC
Rembacken 1999 
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Exclusion criteria: patients not in remission after a maximum of 12 weeks were excluded from the fur-
ther trial, as was any patient who deteriorated clinically
Age (mean SD): unable to differentiate
Sex (M/F): unable to differentiate
Site of disease: unable to differentiate data
Use of concurrent medication: gentamicin 1 week
Treatment before study: prednisolone and in remission for 12 weeks
Number randomised: 57 (probiotic), 59 (placebo)
Number analysed: 52 (probiotic), 50 (placebo)
Postrandomisation exclusion: 14 - withdrawn from study (no reason given)
Interventions E coli (serotype 06:K5:H1) Mutaflor, 2 capsules a day (2.5 x 1010)
Comparison: mesalazine (Asacol formulation) 800 mg three times a day for 12 weeks
Steroid type and dose were dependent upon disease severity
Gentamicin 80 mg three times a day per day for 1 week after entry
Follow up: 12 weeks
Outcomes • Primary outcomes were time to relapse and rate of relapse after successful induction (induction de-
fined as: general well-being with the passage of no more than three formed stools per day, a rectal
mucosa without erythema, granularity or friability as well as histological confirmation)
• Secondary outcome included time to remission
Notes Funded by Sir Jules thorn trust (charity)
Conflicts of interest - not stated
Contacted author in previous review 17 February 2015 - reply received 23 February 2015
Contacted author for current review 13 April 2018 - no reply received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: confirmed via correspondence with author that randomisation was
done centrally by independent pharmacy using software
Allocation concealment
(selection bias)
Low risk Comment: confirmed via correspondence with author that randomisation was





Unclear risk Different intake of medication. Quote: "all patients....to receive either
mesalazine 800 mg three times daily or a non-pathogenic strain of E Coli at a
dose of two capsules twice daily."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No mention in text
Rembacken 1999  (Continued)
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Unclear risk States 'withdrawn' in flow diagram, but no clear reason
Selective reporting (re-
porting bias)
Low risk Trial registration not available, however, all expected outcomes were reported
Other bias High risk Participants were classified according to disease severity and given specific
concomitant treatments based on this classification, this puts the randomisa-
tion into question.
Quote: "Randomisation was then stratified to ensure that the two treatment
groups received the same proportion of patients with mild colitis and procti-
tis...."






Study period: September 2014 to January 2015
Participants Inclusion criteria: > 18 years, histologically-confirmed UC, who despite their pharmacological treat-
ment remained with mild to moderate activity of the disease (according to the Truelove and Witts
scales, mild/moderate baseline UC level =12/5(probiotics), 6/11(control)) and were treated at the colo-
proctology service of a reference hospital
Exclusion criteria: Patients with severe disease activity or concomitant cancer diagnosis, patients re-
ceiving TNF-alpha antagonist drugs
Age (mean SD): 42.6+/-11.8 (probiotics), 53.6+/-10.3 (control) years
Sex (M/F): 12/5(probiotics), 6/11(control)
Site of disease: not stated
Use of concurrent medication: mesalazine (2 g/day on average, maximum dose 3 g/day)
Treatment before study: not stated
Number randomised: 17 (probiotics), 17 (control)
Number analysed: 17 (probiotics), 17 (control)
Postrandomisation exclusion: 0
Interventions • A combination of 6 strains of probiotics (Lactobacillus plantarum, Lactobacillus acidophilus, Lacto-
bacillus rhamnosus, Lactobacillus bifidus, Lactobacillus casei and Bifidobacterium infantis), in doses of
4 x 10 to the power of 7 UFC, before breakfast
• Nutritional treatment
All participants continued to receive their conventional pharmacological treatment.
Follow-up: 3 months
Outcomes • Clinical improvement defined as a decrease of at least 1 point in the Truelove and Witts scale, which
is a combination of clinical and laboratory parameters
Sanchez-Morales 2019 
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• Histological changes, defined as improvement if there was a decrease of at least 1 point in the Gupta
index was observed, and worsening if it increased at least 1 point on the Gupta scale
• Clinical remission, considered in that patient without bloody diarrhoea, without tachycardia, without
fever, without anaemia and normal ESR and/or CRP (provided by author via email on 21 December
2019)
Notes The authors declared no conflict of interest.
Funding not mentioned
Study report written in Spanish. Google Translate was used for the translation.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation is mentioned but no there are not enough details to determine
bias. Emailed author on the 18 December 2019 but no response received
Allocation concealment
(selection bias)
Unclear risk There is no mention of allocation concealment and not enough details to de-






High risk This was an open study and there is no mention of placebo and blinding of
participants or personnel.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Authors mention that biopsies were interpreted by a pathologist who did not
know the clinical status of the patients. However, there is no other mention of
blinding of outcome assessors, and there is not enough information to deter-
mine bias. This was considered unclear risk for the outcome of clinical remis-




Low risk Outcomes reported for all randomised patients. In the methods section au-
thors mention that patients were excluded when they required a change in
pharmacological treatment due to worsening of their illness. However, no
withdrawals or discontinuations are mentioned in the results.
Selective reporting (re-
porting bias)
Low risk Outcomes were not explicitly stated in the methods section and in their result
section the authors report results on food consumption, diarrhoea frequen-
cy and blood in stools, which were not mentioned as an outcome in the meth-
ods section. However, clinical and histological outcomes, as mentioned in the
methods have been reported.





Study period: not stated
Participants Inclusion criteria: active moderate UC
Exclusion criteria: not stated
Age (mean SD): not stated
Solovyeva 2014 
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Sex (M/F): not stated
Site of disease: not stated
Use of concurrent medication: not stated
Treatment before study: not stated
Number randomised: not stated
Number analysed: not stated
Postrandomisation exclusion: not stated
Interventions Two treatment arms
Enterococcus faecium L-3 (3 dragees 3 times/day, oral) plus mesalazine 3 g/day
Stand alone mesalazine 3 g/day
Outcomes • Improvement in clinical activity index
• Improvement in EAI
Notes Funding: not stated
Conflicts of interests: not stated
Only abstract available
Contacted author 23 April 2018 - no response received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Participants were reportedly randomised into groups, no further detail provid-
ed. Quote: "Patients with active moderate ulcerative colitis (47) were random-
ized on 2 groups."
Allocation concealment
(selection bias)





High risk Quote: "patients of the first group received standard therapy by Mesalazine in
a dose 3 g/day, patients of the second group received therapy by Mesalazine in
a dose 3 g/day in a combination with probiotic containing Enterococcus faeci-
um L-3..." Comment: there is no indication of the use placebo in the standard
group
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk Authors appear to have collected data on number of remissions, however, this
was not clearly reported
Solovyeva 2014  (Continued)
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Other bias Low risk Prior to the beginning of treatment both groups of patients were statistical-
ly comparable. Comment: baseline characteristics were probably balanced




Methods Multicentre, double-blind, placebo-controlled, randomised trial
Setting: India, multicentre, tertiary care centre
Study period: 5 June to 7 Aug
Participants Inclusion criteria: >18 with mild-to-moderately active UC UCDAI score 3-9, with minimum sigmoido-
scopic score of 2, extending for more than 15 cm form the anal verge with at least one previously docu-
mented attack of active disease
Exclusion criteria: disease limited to the rectum, evidence of severe disease (UCDAI > 10), concurrent
enteric infection, use of oral steroids within the past 4 weeks, use of antibiotics within the past 2 weeks,
change in dose of oral mesalamine within the past 4 weeks, and use of rectal mesalamine or steroids
within 7 days before entry into the study, patients requiring hospitalisations and imminent need for
surgery, lactating and pregnant women, and those who received any investigational medicines within
3 months were excluded, patients with significant hepatic, renal, endocrine, respiratory, neurologic or
cardiovascular diseases were also excluded.
Age (mean SD): 39.8 (13) (probiotics) 38.3 (12.5) (placebo)
Sex (M/F): 43/3 (probiotic), 45/25 (placebo)
Site of disease: proctitis 0, leT colon involved 21, proctosigmoiditis 38, total colitis/sub 18 (probiotics)
proctitis 0, leT colon involved 26, proctosigmoiditis 28, total colitis/sub 16 (placebo)
Use of concurrent medication: oral mesalamine therapy (taken 4 weeks at stable dose before study
entry) continued to do so, azathioprine or 6-mercaptopurine were maintained on a stable dose for at
least 3 months before entry and throughout the study
Treatment before study: not stated
Number randomised: 77 (probiotic), 70 (placebo)
Number analysed: 55 (probiotic), 29 (placebo)
Postrandomisation exclusion: 17 - worsening symptoms; 18 lost to follow-up, 28 - discontinued thera-
py
Interventions VSL#3, containing 900 billion viable lyophilised bacteria, comprising four strains of lactobacilli (L para-
casei, L Planatarum, L Acidophilus, and L delbrueckii subs bulgaricus), three strains of bifidobacteria (B
longum, B breve and B infantis) and one strain of Streptococcus thermophilus, supplied by VSL pharma-
ceuticals, MD)
4 Sachets, oral, daily
Placebo: maize powder, taken twice daily
Outcomes • Proportion inducing remission
• Adverse events
• Withdrawals
Notes Funded by CD Pharma India Private LT
Conflicts of interests - none declared
Sood 2009 
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Contacted author 13 April 2018 - replied 24 April 2018
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated system used for randomisation. Quote: "The random
numbers were generated by computerized random number. The randomiza-
tion list and numbered packing of the intervention was prepared by a per-
son not involved in the study. Randomization was performed using permut-
ed blocks of 10. There was a separate randomization list for each study center.
Patients were randomized separately at all 3 study enters."
Allocation concealment
(selection bias)
Low risk Quote: "All the randomization numbers were concealed in separate envelopes
and marked by patient number on the outer envelope. Randomization imple-
mentation. The randomization was performed by staK not involved with the
study. The intervention was provided at each center. Patients were assigned
the next serial number (corresponding to the randomization code) of the inter-
vention.”






Unclear risk Contrary to the study report which indicates there was double-blinding, the
protocol suggests that the study might have been triple-blinded. Sealed en-
velopes were used in maintaining blinding, however, it is unclear if blinding of
investigators remained unbroken. Due to this inconsistency between trial reg-
istration and study, it is unclear whether outcome assessment was blinded.
Quote: "The individual sealed envelope method was used to maintain blinding
of the investigators and study participants"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Contrary to the study report which indicates there was double-blinding, the
protocol suggests that the study might have been triple-blinded. Sealed en-
velopes were used in maintaining blinding, however, it is unclear if blinding of
investigators remained unbroken. Due to this inconsistency between trial reg-
istration and study, it is unclear whether outcome assessment was blinded.
Quote: "The individual sealed envelope method was used to maintain blinding




High risk Over 40% attrition
Selective reporting (re-
porting bias)
High risk Trial registration available (CTRI/2008/091/000076), however, not all prespeci-
fied outcomes were reported
Other bias Low risk Both groups comparable. Quote: “The demographic and clinical characteris-
tics such as age, sex, number of previous relapses, extent of disease, and the
use of steroids or immunosuppressive drugs in both groups were comparable”




Methods Multicentre, double-blinded, placebo-controlled, randomised trial
Setting: multicentre, Japan, Hospital
Tamaki 2016 
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Study period: Jan 2007 to May 2009
Participants Inclusion criteria: > 18 years with mild to moderate UC (UC disease activity index (UCDAI) score 3-9)
Exclusion criteria: evidence of severe disease (UCDAI > 10, concurrent enteric infection, use of antibi-
otics within the past 2 weeks, change in dose of oral 5-ASA within the past 4 weeks, and use of rectal
5-ASA or steroids within 7 days before entry into the study. Patients requiring hospitalisations and im-
minent need for surgery, lactating and pregnant women, and those who received any investigational
medicines within 3 months were excluded. Significant hepatic, renal, endocrine, respiratory, neurologi-
cal or cardiovascular disease were also excluded.
Age (mean SD): 44.9 (14.5) (probiotics) 45.5 (13.8) (placebo)
Sex (M/F): 11/17 (probiotic, 16/12 (placebo)
Site of disease: proctitis 0, leT colon involved 17, proctosigmoiditis 10, total colitis/sub 1 (probiotics)
proctitis 0, leT colon involved 19, proctosigmoiditis 7, total colitis/sub 2 (placebo)
Use of concurrent medication: 5-ASA, prednisolone, azathioprine and 6-mercaptopuirne
Treatment before study: not stated
Number randomised: 28 (probiotic), 28 (placebo)
Number analysed: 28 (probiotic), 28 (placebo)
Postrandomisation exclusion: none
Interventions 2-3 x 1011 freeze-dried viable BB536 (Moringa Milk Industry Co)
Placebo: dextrin
Both - Oral three times per day, 8 weeks
Outcomes • Proportion of patients reaching remission (UCDAI scores of 0-2)
• Adverse events
• Withdrawals
Notes Funding - Japanese society for the promotion of science 'Kakenhi' Grants-in-aid for scientific research
Conflicts of interest - none declared
Contacted author 23 April 2018 - no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information on how list was generated. Quote: "randomisation
list, randomisation number was strictly given according to the order of the pa-




Unclear risk Quote: "the study product BB536 was provided in sealed plastic individual





Low risk Placebo blinded
Quote: "randomisation was carried out in a double-blind manner using 1:1 al-
location to the two groups"
Tamaki 2016  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The study was reportedly double-blinded, however, there was insufficient in-




Low risk Attirition rate were similar across groups and ITT analysis was carried out
Selective reporting (re-
porting bias)
High risk Quote: "In contrast, there were no significant differences in stool frequency
and physician's global assessment in either group (data not shown)"
Comment: trial registration not available and non-significant results were
mentioned, but not reported adequately
Other bias Low risk Groups were comparable. Quote: "No significant differences were identified in
terms of demographic characteristics (mean age; sex...."




Methods Double-blind, randomised, placebo-controlled parallel study
Setting: multicentre
Study period: not stated
Participants Inclusion criteria: aged more than 18 years, diagnosis of UC established by previous colonoscopy, with
consistent histology and clinical course, UC involving at least the rectosigmoid region; activity con-
firmed by colonoscopy at the beginning of the study, mild-to moderate relapsing UC, defined as a UC-
DAI score ranging from 3-8, symptoms (relapsing episodes) for less than 4 weeks before study entry, a
minimum endoscopic score of 3 on the UCDAI at screening (mucosal appearance), use of oral 5-ASA at
least 4 weeks before study entry and a stable dose (Mesalazine at least 1.6G/day or balsalazide at 4.5 g/
day) and/or use of azathioprine (at least 1.5 mg/kg/day) or 6-mertcaptopurine (at least 1 mg/kg/day at
least 3 months before study entry at a stable dose
Exclusion criteria: Crohns or pouchitis, a UCDAI score greater than 8 (need for emergency surgery or
the presence of severe disease), use of oral steroids within the last 4 weeks before study entry, use of
antibiotics within the last 2 weeks before study entry, change in dose of oral 5-ASA within the last 4
weeks before study entry and throughout the 8-week study period or a change in dose of oral 6-mer-
captopurine and azathioprine drugs within the last 3 months before the study, use of rectal 5-ASA or
steroids within 1 weeks before entering the study or throughout the 8-week study period, use of probi-
otic preparations either prescribed or over-the-counter within 2 weeks before study entry, use of Non-
steriodal anti-inflammatory for 1 week before and throughout the 8-week study period, significant he-
patic, renal endocrine, respiratory, neurological, or cardiovascular diseases. History of severe adverse
reaction or known hypersensitivity to maltose and/or silicon dioxide, patients requiring hospitalisa-
tions, use of any investigational drug and/or participation in any clinical trial within 3 months before
entering this study
Age (mean ± SD): 47.7 ± 14.1) (probiotics) 46.4 (14.4) (placebo)
Sex (M/F): 49/22 (probiotic), 44/29 (placebo)
Site of disease: proctitis 0, leT colon involved 24, proctosigmoiditis 36, total colitis/sub1 (probiotics)
proctitis 0, leT colon involved 21, proctosigmoiditis 38, total colitis/sub 14 (placebo)
Use of concurrent medication: maintenance oral 5-ASA and/or azathioprine or 6-mercapropurine
Tursi 2010 
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Treatment before study: maintenance oral 5-ASA and/or azathioprine or 6-mercapropurine continued
to do so at stable doses
Number randomised: 71 (probiotic), 73 (placebo)
Number analysed: 65 (probiotic), 66 (placebo)
Postrandomisation exclusion: no patient was withdrawn before treatment assignment
Interventions Probiotic: VSL#3, containing 900 billion viable lyophilised bacteria, comprising four strains of lacto-
bacilli (L paracasei, L Planatarum, L Acidophilus, and L delbrueckii subs bulgaricus), three strains of bifi-
dobacteria (B longum, B breve and B infantis) and one strain of Streptococcus thermophilus, supplied by
VSL pharmaceuticals, MD)
Placebo: contains no lyophilised bacteria
Outcomes • Decrease in UC disease activity index (UCDAI) of 50% of more
• Remission (UCDAI score < 2)
• Improvement in endoscopic scores
• Change in objective symptoms
• Change in subjective symptoms
• Lack of beneficial effects, defined by the need for pharmacological treatment or inability to remain
on the study regimen until week 8
Notes Funding - Sponsored by VSL pharmaceuticals Towson MD
Conflicts of interest - none declared
Contacted author 23 April 2018 - no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation used. Quote: "randomization was carried out in a dou-




Unclear risk Quote: “The study product, VSL # 3, was provided in plastic sealed individual
dose sachets. Placebo was supplied in identical sachets.” Comment: unclear





Low risk Placebo was supplied in identical sachets
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unclear: Quote: “The statistical analysis of all the data sets pertaining to effica-
cy (specifically, primary and secondary end points) and safety specifically, se-
rious adverse events as defined by federal guidelines) has been independently
performed by a biostatistician who is not employed by the corporate entity."





Low risk Atrition rates were similar across groups. ITT analysis applied
Tursi 2010  (Continued)
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Selective reporting (re-
porting bias)
Low risk Trial registration not available, however, all expected outcomes were reported
Other bias Low risk Groups comparable. Quote: “The clinical characteristics of patients in the two
groups were comparable. No significant differences were identified in terms of
demographic characteristics (mean age, male – female..."




Methods Randomised, double-blind, placebo-controlled study
Setting: multicentre, Iran, private practises
Study period: not stated
Participants Inclusion criteria: newly diagnosed or recently relapsed UC, based on clinical, endoscopic, and his-
tological findings and had a mild to moderately active UC according to Truelove and Witts criteria and
clinical activity index ≥ 4 and ≥ 12
Exclusion criteria: substantial cardiac, renal or hepatic diseases, severe immunocompromised pa-
tients, existing or intended pregnancy or breast feeding, regular treatment with NSAID drugs, intestinal
major operation, steroids dependency, known intolerance to sulfur-free preparations of mesalazine,
ulcerative colitis exacerbated by infectious colitis, toxic megacolon, use of antibiotic within 14 days
prior to first visit for more than 1 weeks, use of corticosteroid injection within the last 30 days, use of
immunosuppressive treatment within the last 90 days and use of mesalazine enema or corton enema
within the last 14 days.
Age (mean ± SD): not stated
Sex (M/F): not stated
Site of disease: not stated
Use of concurrent medication: conventional medical treatment for active ulcerative colitis
Treatment before study: not stated
Number randomised: 17 (probiotic), 17 (placebo)
Number analysed: 14 (probiotic), 13 (placebo)
Postrandomisation exclusion: worsening symptoms 2 days after trial starting
Interventions L casei strain ATCC PTA-3945, 5x105 live active cells
Oral, 1 capsule twice daily
Placebo: not gone into detail
Follow-up: 8 weeks
Outcomes • Proportion inducing remission (defined as patient did not have more than 3 well-formed stools per
day and was without visible blood in the stools and any clinical symptoms of ulcerative colitis and had
a clinical activity index < 4)
• Withdrawals
• Adverse events
• Median time to remission (extracted from graph)
Vejdani 2017 
Probiotics for induction of remission in ulcerative colitis (Review)









Cochrane Database of Systematic Reviews
Notes Funding - not stated
Conflicts of interests - none declared
Contacted author 23 April 2018 - no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table used. Quote: “Randomisations were done using a ran-
dom number table with odd numbers for probiotic and even numbers for
placebo; randomisation was stratified according to the use of mesa lazing or
sulfasalazine and to the clinical severity of disease (mild or moderate)"
Allocation concealment
(selection bias)





Low risk Intervention agent and placebo used were similar. Quote: “Placeboes were in-
distinguishable from the L casei preparation”
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The study was reportedly double-blinded however, there is no indication that




High risk Attrition rate was over 20%
Selective reporting (re-
porting bias)
High risk Trial registration not available, however, biochemical tests were recorded both
at entry, remission and relapse and not reported
Other bias Low risk Groups were comparable. Quote: "There was not a significant difference be-
tween the two groups in factors such as age, sex, disease duration and extent,
smoking, education taken and clinical activity index”





Setting: Department of Gastroenterology, Zhenjiang Huanhua Hospital
Study duration: January 2013 to December 2016
Participants Total of 76 UC patients
38 patients in the non-IV group (mild UC 21, severe UC 17)
38 patients in the IV group (mild UC 19, severe UC 19)
Inclusion criteria
• Meet the diagnostic criteria of the "consensus on traditional Chinese medicine diagnosis and treat-
ment of UC"
Zhang 2018a 
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• Patients aged 19 to 50
Exclusion criteria
• Patients who do not meet the diagnostic criteria
• Persons < 19 or > 50
• Intestinal perforation, local stenosis, toxic megacolon
• Pregnant or lactating women
• Those who are allergic to the drugs used in the study
• Those who have severe heart, lung and abdominal diseases
• Severe and refractory patients
• People with mental illness who cannot co-operate with treatment
Age (mean ± SD): 36 +/- 6.9 in non-IV group; 36 +/- 8.9 in IV group
Sex (M/F): 20/28 in non-IV group; 22/26 in IV group
Site of disease: leT half colon 20, whole colon 18 in non-IV group; leT colon 18, whole colon 20 in IV
group
Use of concurrent medication: not stated
Treatment before study: not stated
Number randomised: 38 in IV group, 38 in non-IV group
Number analysed: not stated
Postrandomisation exclusion: not stated
Interventions • IV group (confusingly, alternatively called observation or control group in the article): mesalazine (0.25
g/tablet, 4 tablets/day) + bifidobacterium quadruple live bacteria tablets (0.5 g/tablet, 3x3 tablets/
day)
• Non-IV group (confusingly, alternatively called observation or control group in the article): mesalazine
only (0.25 g/tablet, 4 tablets/day)
Follow-up: 8 weeks
Outcomes • Changes in Mayo score (decrease = (mayo score before treatment - Mayo score after treatment/Mayo
score before treatment x 100%))
• Serum hs-CRP
• Serum IL-4 and IL-8
• Safety parameters
Notes Conflict of interest and funding are not stated in the article.
Author was contacted via the email provided in the article on the 18 December 2019 and we received
an error message that the email was not delivered.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not discussed in the article. Author was contacted via the email provided in
the article on the 18 December 2019 and we received an error message that
the email was not delivered.
Allocation concealment
(selection bias)
Unclear risk Not discussed in the article
Zhang 2018a  (Continued)
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Unclear risk Not discussed in the article
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Not discussed in the article
Selective reporting (re-
porting bias)
Low risk All stated outcomes were reported
Other bias Unclear risk Funding and conflict of interest not discussed in the article
Zhang 2018a  (Continued)
5-ASA: 5 Aminosalycilic acid; BFM: bifidobacteria-fermented milk; CD: Crohn's disease; CFU: colony forming unit; CRP: c-reactive protein;
DAI: disease activity index; EcN: escherichia coli Nissle; ESR: erythrocyte sedimentation rate; hs-CRP: high sensitivity c-reactive protein;
IL-4: interleukin 4; IL-8: interleukin 8; ITT: intention to treat; IV: intervention; LCAI: Lichtiger colitis activity index; NSAIDs: non-steroidal anti-
inflammatory drugs; RCT: randomised controlled trial; SASP: salazosulphapyridine; SD: standard deviation; UC: ulcerative colitis; UCDAI:
ulcerative colitis disease activity index; VAS: visual analogue scales
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ballini 2019 Mixed group of UC and CD
Bataga 2015 Cannot find article
Bjarnason 2019 Maintenance study
Fujimori 2009 Wrong comparator - data for induction and remission presented together
IRCT20120415009475N5 IBD patients not recruited for the purpose of inducing or maintaining remission – possibly mixed
disease type and activity. Author contacted for data as trial was registered retrospectively.
Ishikawa 2003 Wrong comparator - not aiming for induction
Krag 2013 Wrong study type: cross-over study that presented results together for induction and remission
NCT00374725 Insufficient information: emailed author with no reply
NCT00895336 Insufficient information; emailed author with no reply
Santana 2010 Wrong study type: patients not randomised
Turcotte 2011 Wrong study type: commentary piece
IBD: inflammatory bowel disease
 
Characteristics of studies awaiting assessment [ordered by study ID]
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Methods RCT, single centre
Setting: The First Affiliated Hospital of Fujian Medical University
Study duration: January 2015 to June 2016
Participants 40 with IBD randomised (19 control group, 21 observation group)
UC total: 31, CD total: 9; UC control 15, CD IV 4; CD control 4, CD IV 5
Inclusion: confirmed IBD diagnosis with mild to moderate symptoms as per the current stan-
dards in China; no previous probiotic treatment; no allergy to drugs used in the present study; cog-
nizance of the purpose of the present study and willingness to sign an informed consent
Exclusion: severe heart, liver, kidney and other systemic diseases; pregnancy or lactation; unre-
sponsive to medical treatment and with complications; immune system disorders
Sex (M/F): 10/9 control group; 10/11 observation group
Age (mean +/- SD): 39.97 +/- 8.68 control group; 42.56 +/- 7.58 observation group
Site of disease: not stated
Use of medication: not stated
Length of time remission at study entry: not stated
Number randomised: 40
Number assessed: not stated
Postrandomisation exclusion: not stated
Follow- up: 40 days
Interventions IV: pentasa (mesalazine extended action tablet) as in the control regimen + probiotics (2 tablets Bi-
fico once and three times a day + "a largely liquid-based high nutrition diet"
control: 1-2 pentasa tablets once and three times a day and a maintenance dose of 1 tablet once
and three times a day




Notes Mixed: contacted author for UC data
This work was supported by the Fujian Province Natural Science Fund Project





Setting: Chunan County First People's Hospital and Taizhou Hospital
Study duration: February 2016 to September 2017
Fang 2019 
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Participants 84 patients with UC (42 control, 42 IV)
control: 18 mild, 24 moderate; IV: 19 mild, 23 moderate
Inclusion: meet the relevant diagnostic criteria for UC, confirmed by colonoscopy, barium enema,
etc; course of disease ≥ 4 weeks; accompanied by persistent or recurrent diarrhoea, hemorrhag-
ic stool with abdominal pain, acute aftermath etc; age ≥ 18 years; volunteer to participate in this
study and sign informed consent
Exclusion: those with allergies; combined with infectious colitis such as amoebiasis, bacterial dis-
ease, intestinal tuberculosis, chronic schistosomiasis; severe intestinal perforation, intestinal ob-
struction, toxic colonic dilatation etc; people with unconsciousness, serious insufficiency of impor-
tant organs such as heart and kidney; people with radiation colitis, ischaemic colitis, Crohn's dis-
ease, mental illnesses, history of drug and alcohol abuse; pregnant, lactating women
Sex (M/F): 26/16 control; 28/14 IV
Age: 45.12 +/- 6.21 control; 45.13 +/- 6.2 IV
Site of disease: whole colon 15, right half colon 19, leT half colon 8 control; whole colon 16, right
half colon 17, leT half colon 9
Use of medication: not stated
Length of time remission at study entry: not stated
Number randomised: 84
Number assessed: not stated
Postrandomisation exclusion: not stated
Follow-up: 2 months
Interventions IV: mesalazine + gold bifid
control: mesalazine only
Outcomes • Inflammation markers (IL-10, TNF-α, IL-18, sIL-2R)
• Lesion activity scores (modified Mayo scores)
• Clinical efficacy
• Anorectal motility
Notes Disease activity to be clarified. 95 versus 76% effective rate
Main article in Chinese. Google translate was used for the translation.




Methods RCT, single centre
Study duration: May 2014 to February 2018
Setting: Bai'an Affiliation Sanxia Central Hospital of Chongqing
Participants Abstract: 120 UC patients (control 60, IV 60)
Main text: 360 UC patients (control 180, IV 180)
Huang 2018 
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Inclusion: not stated
Exclusion: not stated
Sex (M/F): 81/99 control; 90/90 IV
Age (mean +/- SD): 41.5 +/- 8.3 control; 42.2 +/- 9.4 IV
Site of disease: not stated
Use of medication: not stated
Length of time remission at study entry: not stated
Number randomised: 120 or 360
Number assessed: not stated
Postrandomisation exclusion: not stated
Follow- up: 8 weeks
Interventions Control: mesalazine only
IV: mesalazine + bifid triple viable capsules
enteric-coated tablet of mesalazine (Sunflower Group
Jiamusi Luling Pharmaceutical Co. Ltd. 0.25 g/tablet,
batch No.: 13001830), four tablets oral administration
before meal, 3 time/day. Those in the research group would
additionally take two bifid triple viable capsules
(Jincheng Haisi Pharmaceutical Co. Ltd. 0.21 g/capsule,
Batch No.: 13012365) prior to meal, 3 times/day
Outcomes • Evaluation of clinical efficacy
• Disease Activity Index (DAI) of UC
• Score of clinical symptoms,
• Changes in inflammatory factors (TNF-α, IL-8 and IL-10)
• Adverse reactions
Notes Unclear whether active or inactive UC - emailed authors. Effectiveness rate = 90% versus 72%




Methods RCT, single centre
Setting: Department of Gastroenterology, Anji County People's Hospital of Huzhou City
Study duration: August 2014 to November 2016
Participants 86 UC patients (43 control, 43 IV)
Inclusion criteria: all who meet the diagnosis of ulcerative colitis in the "Consensus Opinions on
the Diagnosis and Treatment of Inflammatory Bowel Diseases in China" formulated by the Collabo-
Shi 2018 
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rative Group of Inflammatory Bowel Diseases of the Chinese Medical Association Gastroenterology
Branch Criterion, with typical clinical manifestations (diarrhoea, mucus, pus, blood, stool, etc.) and
colonoscopy (continuous, diffuse distribution of ulcer surface); patients agreed to the study and
signed informed consent
Exclusion criteria: those who used contraindications to the study; those who had poor compli-
ance during treatment; other reasons were not suitable for inclusion in the study.
Sex (M/F): IV: 14/27; control: 17/24
Age (mean +/- SD): IV: 47.1+/-4.9; control: 47.3+/-6.2
Site of disease: not stated
Use of medication: not stated
Length of time remission at study entry: not stated
Number randomised: 86
Number assessed: not stated
Postrandomisation exclusion: not stated
Follow-up: treatment 2 months + 6 months
Interventions IV: Bacillus subtilis and Enterococcus faecium + mesalazine
control; mesalazine only
Mesalazine enteric-coated tablets (Sunflower Pharmacy, Chinese Medicine Standard: H19980148,
(Specification: 0.25g/tablet), oral, 1 g/time, 6 h/time; the observation group was combined with
the Bacillus subtilis double live enteric-coated capsules (trade name: Mei Changan, Beijing Han-
mei Pharmaceutical Co. Ltd. based on the control group). Company, National Medicine Standard:
S20030087, Specification: 250 mg/capsule), 500 mg, orally, 3 times/day; two groups of patients
were continuously taking medication for 2 months
Outcomes • Inflammation markers (IL-6, IL-8, IL-10, TNF-α, MDA, SOD, COX-2, NF-κΒ)
• Clinical curative effect
• Time to symptom relief
• Rachmitewitz and Sutherland scores
Notes Disease activity to be clarified. 93% versus 76% effective rate
Article in Chinese. Google Translate was used for the translation.




Methods RCT, single centre, prospective, open-label
Study duration: May 2015 to December 2016
Participants 45 IBD patients (25 IV, 20 control)
UC = 15, CD = 10
Inclusion/exclusion: "Patients with IBD participated in the study. In the trial, CD Activity Index for
CD and Truelove-Witts scoring systems for UC were used for disease assessment scores. If the score
was < 450, patients with CD were admitted to the study. If the score was higher, patients with UC
Yilmaz 2019 
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were not admitted to the study. Volunteers also had to be > 18 years old. Patients with alcohol con-
sumption > 20 g/day, allergies or intolerance to milk, antibiotic treatment within the last 1 month,
column or bowel operation history up to 3 months before the start of the study, and the presence
of active infection within 1 month prior to the start of the study or during the study were exclud-
ed from the study. In addition, if a patient requested to leave on his/her own will, or if kefir was not
consumed continuously for 2 weeks, the trial protocol was assessed and was not approved."
Sex (M/F): IV: total 13/12, UC 9/6, CD: 4/6, control: total 10/10, UC: 4/6, CD: 6/4
Age (median): IV: 33, control: 43
Site of disease: IV: UC colon 15, CD colon 1, ileum 6, colon + ileum 3; control: UC colon 10, CD ileum
10
Use of medication: not stated
Length of time remission at study entry: not stated
Number randomised: 45?
Number assessed: 45
Postrandomisation exclusion: either 0 or 3. Authors mention 3 patients leT the trial willingly,
however participant and completer number are the same (n = 45)
Follow-up: 4 weeks
Interventions IV: 400 mL/day kefir x 2 day
Control:unclear
"The control group did not consume placebo because it was not possible to prepare a control prod-
uct with a similar flavor, texture, and taste as those of kefir. Ayran and yogurt were similar to kefir,
but they also have Lactobacillus and can affect the microbiota results."
Outcomes • Symptoms diary questionnaire
• Effects on Lactobacillus flora and their biochemical properties
Notes Disease activity not clear. 96% versus 85% effective rate




Methods RCT, single centre
Setting: Department of Gastroenterology, Longyou County People's Hospital, Luzhou, Zhejiang
Province
Study duration: October 2016 to November 2017
Participants 110 UC patients (55 control (38 UC, 17 CD); 55 observation (36 UC, 19 CD))
Inclusion: in accordance with the diagnostic criteria of the "Consensus on the diagnosis and treat-
ment of inflammatory bowel disease in China" formulated by the Chinese Medical Association; no
significant abnormalities in liver and kidney function; no other severe chronic diseases; informed
consent
Exclusion: severe liver and kidney diseases; intestinal diseases such as intestinal tuberculosis,
Crohn's disease, intestinal tumours; hormones, 5-aminosalicylic acid, and intestinal probiotics for
nearly 4 weeks; patients with other drugs; patients who are allergic to drugs such as mesalazine,
Zhang 2018b 
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bifidobacterium quadruplex, etc.; pregnant and lactating women; patients with mental illness; pa-
tients who do not co-operate with treatment; younger than 18 years old
Sex (M/F): IV 29/26; control 32/23
Age (mean +/- SD): IV: 44.6+/-5.8; control 45.3 +/-5.5
Site of disease: not stated
Use of medication: not stated
Length of time remission at study entry: not stated
Number randomised:
Number assessed: not stated
Postrandomisation exclusion: not stated
Follow-up: 2 months
Interventions IV: Bifidobacterium quadruplex bacteria tablets + mesalazine
Control: mesalazine
Both groups were given mesalazine enteric-coated tablets (trade name: Huidi,
Manufacturer: Sunflower Pharmaceutical Group Jiamusi Luling Pharmaceutical Co., Ltd., Nation-
al Medicine Standard H19980148, 0.25 g/tablet), oral, 1 g/time, 3 times/day. The observation group
was given a bifidobacterium quadruple live bacteria tablets (brand name: Siliankang, manufactur-
er: Hangzhou Longda Xinke Biopharmaceutical Co., Ltd., National Medicine Standard)
S20060010, 0.5 g/tablet), oral, 1.5 g/time, 3 times/day
Outcomes • Total effective rate
• Lipid peroxidation injury indexes
• Inflammatory factors
• Peripheral T cell subsets
• Adverse reactions
Notes Article in Chinese. Google Translate was used for the translation.
Funding and conflict of interest were not discussed in the article.
Zhang 2018b  (Continued)
CD: Crohn's disease; IBD: inflammatory bowel disease; IV: intervention; SD: standard deviation; UC: ulcerative colitis;
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Multistrain probiotics reduces UC depression and anxiety scores
Methods RCT, double-blind, parallel assignment
Participants 60 UC patients
Interventions IV: multistrain probiotic product (DSF)
Control: placebo
NCT04006977 
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Outcomes Primary outcome measures: reduction of anxiety and depression scores (time frame: 0 week, 8
weeks, 12 weeks, 16 weeks) reduction of anxiety and depression scores (with points as standard
units) using HADS at 8 weeks and 16 weeks after randomised treatment
Secondary outcome measures: clinical response (time frame: 4 weeks, 8 weeks, 12 weeks, 16
weeks) measured by a ≥ 1.5(3) point reduction in Simple Clinical Colitis Activity Index score at week
8 and 16
Clinical remission (time frame: 4 weeks, 8 weeks, 12 weeks, 16 weeks) measured by Simple Clinical
Colitis Activity Index score ≤ 5(2) points at week 8 and 16
Endoscopic remission/response (time frame: 0 week, 16 weeks) measured by a Mayo endoscop-
ic subscore of < 1 point, or at least a 1 point reduction from baseline in the endoscopy subscore at
week 16
Changes in faecal-associated microbiota following probiotic therapy (time frame: 0 week, 16
weeks); changes in faecal-associated microbiota using 16S ribosomal RNA sequencing and changes
in the metabolomic profile of the faeces following probiotic therapy (at baseline and 16 weeks) will
be assessed, stratified by both change in Simple Clinical Colitis Activity Index score following probi-
otic therapy and randomisation.
Identification of potential stressors (time frame: 0 weeks, 16 weeks). Participants will be asked to
complete a modified practical and family problem list to identify 13 potential stressors.
Adverse events (time frame: 4 weeks, 8 weeks, 12 weeks, 16 weeks) were assessed at week 8 and 16
by patient survey.
Starting date October 2019
Contact information Prof Jie Liang liangjie@fmmu.edu.cn
Notes Sponsors and collaborators: Xijing Hospital of Digestive Diseases, MENDES SA
NCT04006977  (Continued)
DSF: De Simone fomulation; HADS: hospital anxiety and depression scale; RNA: ribonucleic acid; UC: ulcerative colitis
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Probiotics versus placebo





Statistical method Effect size
1 Clinical remission 9 594 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.19, 2.54]
2 Clinical remission: subgroup analysis
by age
9 594 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.19, 2.54]
2.1 Adult population 7 525 Risk Ratio (M-H, Random, 95% CI) 1.49 [1.07, 2.08]
2.2 Paediatric population 2 69 Risk Ratio (M-H, Random, 95% CI) 3.83 [1.69, 8.66]
3 Clinical remission: subgroup analysis
by number of strains
9 594 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.19, 2.54]
3.1 Single strain 4 220 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.79, 2.63]
3.2 Multiple strains 5 374 Risk Ratio (M-H, Random, 95% CI) 2.02 [1.31, 3.12]
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Statistical method Effect size
4 Histological remission 1 34 Risk Ratio (M-H, Fixed, 95% CI) 2.5 [0.56, 11.16]
5 Disease improvement 3   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Clinical improvement 2 54 Risk Ratio (M-H, Fixed, 95% CI) 2.29 [1.13, 4.63]
5.2 Endoscopic improvement 1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [1.03, 2.05]
5.3 Histological improvement 1 34 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [1.09, 3.68]
6 Clinical activity scores 1   Mean Difference (IV, Fixed, 95%
CI)
Totals not selected
7 Histology scores 3   Std. Mean Difference (IV, Fixed,
95% CI)
Totals not selected
8 Biochemical markers of inflammation 1   Mean Difference (IV, Fixed, 95%
CI)
Totals not selected
8.1 TNF-alpha 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
8.2 IL-10 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
8.3 IL-1beta 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
8.4 IL-8 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
9 Minor adverse events 7 520 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.42, 2.59]
10 Serious adverse events 7 526 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.66]
11 Withdrawal due to adverse events 4 401 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.42, 1.72]
 
 
Analysis 1.1.   Comparison 1 Probiotics versus placebo, Outcome 1 Clinical remission.
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kato 2004 4/10 3/10 7.1% 1.33[0.4,4.49]
Matthes 2010 20/70 2/20 5.95% 2.86[0.73,11.2]
Miele 2009 13/14 4/15 11.2% 3.48[1.49,8.16]
Oliva 2011 5/20 0/20 1.69% 11[0.65,186.62]
Sanchez-Morales 2019 1/17 0/17 1.39% 3[0.13,68.84]
Sood 2009 33/77 11/70 15.6% 2.73[1.5,4.97]
Tamaki 2016 15/28 12/28 16.66% 1.25[0.72,2.17]
Tursi 2010 31/71 23/73 19.27% 1.39[0.9,2.13]
Favours placebo 1000.01 100.1 1 Favours probiotic
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Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Vejdani 2017 14/17 13/17 21.13% 1.08[0.76,1.52]
   
Total (95% CI) 324 270 100% 1.73[1.19,2.54]
Total events: 136 (Probiotic), 68 (Placebo)  
Heterogeneity: Tau2=0.15; Chi2=17.89, df=8(P=0.02); I2=55.29%  
Test for overall effect: Z=2.84(P=0)  
Favours placebo 1000.01 100.1 1 Favours probiotic
 
 
Analysis 1.2.   Comparison 1 Probiotics versus placebo, Outcome 2 Clinical remission: subgroup analysis by age.
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Adult population  
Kato 2004 4/10 3/10 7.1% 1.33[0.4,4.49]
Matthes 2010 20/70 2/20 5.95% 2.86[0.73,11.2]
Sanchez-Morales 2019 1/17 0/17 1.39% 3[0.13,68.84]
Sood 2009 33/77 11/70 15.6% 2.73[1.5,4.97]
Tamaki 2016 15/28 12/28 16.66% 1.25[0.72,2.17]
Tursi 2010 31/71 23/73 19.27% 1.39[0.9,2.13]
Vejdani 2017 14/17 13/17 21.13% 1.08[0.76,1.52]
Subtotal (95% CI) 290 235 87.11% 1.49[1.07,2.08]
Total events: 118 (Probiotic), 64 (Placebo)  
Heterogeneity: Tau2=0.07; Chi2=10.5, df=6(P=0.11); I2=42.85%  
Test for overall effect: Z=2.33(P=0.02)  
   
1.2.2 Paediatric population  
Miele 2009 13/14 4/15 11.2% 3.48[1.49,8.16]
Oliva 2011 5/20 0/20 1.69% 11[0.65,186.62]
Subtotal (95% CI) 34 35 12.89% 3.83[1.69,8.66]
Total events: 18 (Probiotic), 4 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.67, df=1(P=0.41); I2=0%  
Test for overall effect: Z=3.23(P=0)  
   
Total (95% CI) 324 270 100% 1.73[1.19,2.54]
Total events: 136 (Probiotic), 68 (Placebo)  
Heterogeneity: Tau2=0.15; Chi2=17.89, df=8(P=0.02); I2=55.29%  
Test for overall effect: Z=2.84(P=0)  
Test for subgroup differences: Chi2=4.42, df=1 (P=0.04), I2=77.38%  
Favours probiotics 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.3.   Comparison 1 Probiotics versus placebo, Outcome
3 Clinical remission: subgroup analysis by number of strains.
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Single strain  
Matthes 2010 20/70 2/20 5.95% 2.86[0.73,11.2]
Favours probiotics 1000.01 100.1 1 Favours placebo
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Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Oliva 2011 5/20 0/20 1.69% 11[0.65,186.62]
Tamaki 2016 15/28 12/28 16.66% 1.25[0.72,2.17]
Vejdani 2017 14/17 13/17 21.13% 1.08[0.76,1.52]
Subtotal (95% CI) 135 85 45.43% 1.44[0.79,2.63]
Total events: 54 (Probiotic), 27 (Placebo)  
Heterogeneity: Tau2=0.18; Chi2=7, df=3(P=0.07); I2=57.14%  
Test for overall effect: Z=1.18(P=0.24)  
   
1.3.2 Multiple strains  
Kato 2004 4/10 3/10 7.1% 1.33[0.4,4.49]
Miele 2009 13/14 4/15 11.2% 3.48[1.49,8.16]
Sanchez-Morales 2019 1/17 0/17 1.39% 3[0.13,68.84]
Sood 2009 33/77 11/70 15.6% 2.73[1.5,4.97]
Tursi 2010 31/71 23/73 19.27% 1.39[0.9,2.13]
Subtotal (95% CI) 189 185 54.57% 2.02[1.31,3.12]
Total events: 82 (Probiotic), 41 (Placebo)  
Heterogeneity: Tau2=0.08; Chi2=5.89, df=4(P=0.21); I2=32.07%  
Test for overall effect: Z=3.18(P=0)  
   
Total (95% CI) 324 270 100% 1.73[1.19,2.54]
Total events: 136 (Probiotic), 68 (Placebo)  
Heterogeneity: Tau2=0.15; Chi2=17.89, df=8(P=0.02); I2=55.29%  
Test for overall effect: Z=2.84(P=0)  
Test for subgroup differences: Chi2=0.8, df=1 (P=0.37), I2=0%  
Favours probiotics 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.4.   Comparison 1 Probiotics versus placebo, Outcome 4 Histological remission.
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sanchez-Morales 2019 5/17 2/17 100% 2.5[0.56,11.16]
   
Total (95% CI) 17 17 100% 2.5[0.56,11.16]
Total events: 5 (Probiotic), 2 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.2(P=0.23)  
Favours probiotic 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.5.   Comparison 1 Probiotics versus placebo, Outcome 5 Disease improvement.
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.5.1 Clinical improvement  
Kato 2004 7/10 3/10 42.86% 2.33[0.83,6.54]
Sanchez-Morales 2019 9/17 4/17 57.14% 2.25[0.86,5.92]
Subtotal (95% CI) 27 27 100% 2.29[1.13,4.63]
Total events: 16 (Probiotic), 7 (Placebo)  
Favours probiotics 1000.01 100.1 1 Favours placebo
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Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.96); I2=0%  
Test for overall effect: Z=2.29(P=0.02)  
   
1.5.2 Endoscopic improvement  
Tursi 2010 41/71 29/73 100% 1.45[1.03,2.05]
Subtotal (95% CI) 71 73 100% 1.45[1.03,2.05]
Total events: 41 (Probiotic), 29 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.12(P=0.03)  
   
1.5.3 Histological improvement  
Sanchez-Morales 2019 14/17 7/17 100% 2[1.09,3.68]
Subtotal (95% CI) 17 17 100% 2[1.09,3.68]
Total events: 14 (Probiotic), 7 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.23(P=0.03)  
Favours probiotics 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.6.   Comparison 1 Probiotics versus placebo, Outcome 6 Clinical activity scores.
Study or subgroup Probiotic Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Miele 2009 14 10.9 (0) 15 11.1 (0) Not estimable
Favours probiotics 5025-50 -25 0 Favours placebo
 
 
Analysis 1.7.   Comparison 1 Probiotics versus placebo, Outcome 7 Histology scores.
Study or subgroup Probiotic Placebo Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Kato 2004 10 3 (0.5) 9 3.6 (0.7) -0.95[-1.91,0.01]
Miele 2009 14 2.2 (0) 15 3.3 (0) Not estimable
Oliva 2011 16 0.6 (0.5) 15 2.9 (0.8) -3.38[-4.53,-2.24]
Favours probiotic 10050-100 -50 0 Favours placebo
 
 
Analysis 1.8.   Comparison 1 Probiotics versus placebo, Outcome 8 Biochemical markers of inflammation.
Study or subgroup Probiotic Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.8.1 TNF-alpha  
Oliva 2011 16 10 (3) 15 30 (3) -20[-22.11,-17.89]
   
1.8.2 IL-10  
Oliva 2011 16 100 (20) 15 26 (19) 74[60.27,87.73]
   
Favours probiotic 10050-100 -50 0 Favours placebo
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Study or subgroup Probiotic Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.8.3 IL-1beta  
Oliva 2011 16 20 (24) 15 104 (26) -84[-101.65,-66.35]
   
1.8.4 IL-8  
Oliva 2011 16 10 (12) 15 28 (12) -18[-26.45,-9.55]
Favours probiotic 10050-100 -50 0 Favours placebo
 
 
Analysis 1.9.   Comparison 1 Probiotics versus placebo, Outcome 9 Minor adverse events.
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kato 2004 0/10 0/10   Not estimable
Matthes 2010 37/70 10/20 32.38% 1.06[0.65,1.73]
Miele 2009 0/14 0/15   Not estimable
Sood 2009 14/77 0/70 8.1% 26.4[1.6,434.44]
Tamaki 2016 1/28 0/28 6.69% 3[0.13,70.64]
Tursi 2010 8/71 9/73 26.53% 0.91[0.37,2.24]
Vejdani 2017 4/17 12/17 26.29% 0.33[0.13,0.83]
   
Total (95% CI) 287 233 100% 1.04[0.42,2.59]
Total events: 64 (Probiotic), 31 (Placebo)  
Heterogeneity: Tau2=0.6; Chi2=12.88, df=4(P=0.01); I2=68.94%  
Test for overall effect: Z=0.09(P=0.92)  
Favours probiotics 5000.002 100.1 1 Favours placebo
 
 
Analysis 1.10.   Comparison 1 Probiotics versus placebo, Outcome 10 Serious adverse events.
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Kato 2004 0/10 0/10   Not estimable
Matthes 2010 0/70 0/20   Not estimable
Miele 2009 0/14 0/15   Not estimable
Oliva 2011 0/20 0/20   Not estimable
Sood 2009 0/77 0/70   Not estimable
Tamaki 2016 0/28 0/28   Not estimable
Tursi 2010 0/71 5/73 100% 0.09[0.01,1.66]
   
Total (95% CI) 290 236 100% 0.09[0.01,1.66]
Total events: 0 (Probiotic), 5 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.62(P=0.11)  
Favours probiotic 5000.002 100.1 1 Favours placebo
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Analysis 1.11.   Comparison 1 Probiotics versus placebo, Outcome 11 Withdrawal due to adverse events.
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kato 2004 0/10 1/10 4.94% 0.33[0.02,7.32]
Matthes 2010 16/70 3/20 28.31% 1.52[0.49,4.71]
Sood 2009 17/77 18/70 61.09% 0.86[0.48,1.53]
Tursi 2010 0/71 5/73 5.66% 0.09[0.01,1.66]
   
Total (95% CI) 228 173 100% 0.85[0.42,1.72]
Total events: 33 (Probiotic), 27 (Placebo)  
Heterogeneity: Tau2=0.12; Chi2=3.76, df=3(P=0.29); I2=20.3%  
Test for overall effect: Z=0.45(P=0.65)  
Favours probiotic 1000.01 100.1 1 Favours placebo
 
 
Comparison 2.   Probiotics versus 5-aminosalicylic acid (5-ASA) (mesalazine)





Statistical method Effect size
1 Clinical remission 1 116 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.73, 1.16]
2 Clinical activity scores 1 76 Mean Difference (IV, Fixed, 95% CI) -2.07 [-3.22, -0.92]
3 Biochemical markers of inflamma-
tion
1 228 Mean Difference (IV, Fixed, 95% CI) -3.16 [-3.57, -2.75]
3.1 Serum IL-4 1 76 Mean Difference (IV, Fixed, 95% CI) 2.53 [0.47, 4.59]
3.2 Serum IL-8 1 76 Mean Difference (IV, Fixed, 95% CI) -66.1 [-71.63, -60.57]
3.3 hs-CRP 1 76 Mean Difference (IV, Fixed, 95% CI) -3.03 [-3.45, -2.61]
4 Minor adverse events 2 192 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.56, 2.70]
5 Serious adverse events 1 116 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.22]
6 Withdrawal due to adverse events 1 116 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.22]
 
 
Analysis 2.1.   Comparison 2 Probiotics versus 5-aminosalicylic
acid (5-ASA) (mesalazine), Outcome 1 Clinical remission.
Study or subgroup Probiotic 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rembacken 1999 39/57 44/59 100% 0.92[0.73,1.16]
   
Total (95% CI) 57 59 100% 0.92[0.73,1.16]
Total events: 39 (Probiotic), 44 (5-ASA)  
Heterogeneity: Not applicable  
Favours 5-ASA 1000.01 100.1 1 Favours probiotic
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Study or subgroup Probiotic 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Test for overall effect: Z=0.73(P=0.46)  
Favours 5-ASA 1000.01 100.1 1 Favours probiotic
 
 
Analysis 2.2.   Comparison 2 Probiotics versus 5-aminosalicylic
acid (5-ASA) (mesalazine), Outcome 2 Clinical activity scores.
Study or subgroup Probiotic 5-ASA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Zhang 2018a 38 2.7 (2.3) 38 4.8 (2.8) 100% -2.07[-3.22,-0.92]
   
Total *** 38   38   100% -2.07[-3.22,-0.92]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.53(P=0)  
Favours probiotic 10050-100 -50 0 Favours 5-ASA
 
 
Analysis 2.3.   Comparison 2 Probiotics versus 5-aminosalicylic acid (5-
ASA) (mesalazine), Outcome 3 Biochemical markers of inflammation.
Study or subgroup Probiotic 5-ASA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.3.1 Serum IL-4  
Zhang 2018a 38 32.4 (4.4) 38 29.9 (4.8) 3.98% 2.53[0.47,4.59]
Subtotal *** 38   38   3.98% 2.53[0.47,4.59]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.4(P=0.02)  
   
2.3.2 Serum IL-8  
Zhang 2018a 38 152.3 (10.9) 38 218.4 (13.6) 0.55% -66.1[-71.63,-60.57]
Subtotal *** 38   38   0.55% -66.1[-71.63,-60.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=23.41(P<0.0001)  
   
2.3.3 hs-CRP  
Zhang 2018a 38 2.1 (1.3) 38 5.1 (0.2) 95.47% -3.03[-3.45,-2.61]
Subtotal *** 38   38   95.47% -3.03[-3.45,-2.61]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=14.11(P<0.0001)  
   
Total *** 114   114   100% -3.16[-3.57,-2.75]
Heterogeneity: Tau2=0; Chi2=526.59, df=2(P<0.0001); I2=99.62%  
Test for overall effect: Z=15.05(P<0.0001)  
Test for subgroup differences: Chi2=526.59, df=1 (P<0.0001), I2=99.62%  
Favours probiotic 10050-100 -50 0 Favours 5-ASA
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Analysis 2.4.   Comparison 2 Probiotics versus 5-aminosalicylic
acid (5-ASA) (mesalazine), Outcome 4 Minor adverse events.
Study or subgroup Probiotic 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rembacken 1999 9/57 7/59 69.63% 1.33[0.53,3.33]
Zhang 2018a 3/38 3/38 30.37% 1[0.22,4.65]
   
Total (95% CI) 95 97 100% 1.23[0.56,2.7]
Total events: 12 (Probiotic), 10 (5-ASA)  
Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%  
Test for overall effect: Z=0.52(P=0.61)  
Favours probiotics 1000.01 100.1 1 Favours 5-ASA
 
 
Analysis 2.5.   Comparison 2 Probiotics versus 5-aminosalicylic
acid (5-ASA) (mesalazine), Outcome 5 Serious adverse events.
Study or subgroup Probiotic 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rembacken 1999 0/57 2/59 100% 0.21[0.01,4.22]
   
Total (95% CI) 57 59 100% 0.21[0.01,4.22]
Total events: 0 (Probiotic), 2 (5-ASA)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.02(P=0.31)  
Favours probiotics 2000.005 100.1 1 Favours 5-ASA
 
 
Analysis 2.6.   Comparison 2 Probiotics versus 5-aminosalicylic acid (5-
ASA) (mesalazine), Outcome 6 Withdrawal due to adverse events.
Study or subgroup Probiotic 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rembacken 1999 0/57 2/59 100% 0.21[0.01,4.22]
   
Total (95% CI) 57 59 100% 0.21[0.01,4.22]
Total events: 0 (Probiotic), 2 (5-ASA)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.02(P=0.31)  
Favours probiotics 1000.01 100.1 1 Favours 5-ASA
 
 
Comparison 3.   Probiotics plus 5-aminosalicylic acid (5-ASA) (mesalazine) versus 5-ASA (mesalazine)




Statistical method Effect size
1 Remission (based on Sunderland disease activity
index)
1 84 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [1.01, 1.47]
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Analysis 3.1.   Comparison 3 Probiotics plus 5-aminosalicylic acid (5-ASA) (mesalazine) versus
5-ASA (mesalazine), Outcome 1 Remission (based on Sunderland disease activity index).
Study or subgroup Probiot-
ic + 5-ASA
5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Liu 2014 39/42 32/42 100% 1.22[1.01,1.47]
   
Total (95% CI) 42 42 100% 1.22[1.01,1.47]
Total events: 39 (Probiotic + 5-ASA), 32 (5-ASA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.05(P=0.04)  
Favours 5-ASA 1000.01 100.1 1 Favours probiotic + 5-ASA
 
 
A D D I T I O N A L   T A B L E S
 
Study ID Number in-
duced















Absence of rectal bleeding, a rectal mu-
cosa without erythaema, granularity, or




























Occurrence or worsening of symptoms,
accompanied by an increase in LCAI > 3,
sufficient to require treatment with cor-
ticosteroids, azathioprine/immunosup-









Oliva 2011 5/20 versus
0/20
25% versus 0%
Final DAI score < 2 points Not re-
ported










General well-being with the passage
of no more than three formed stools
per day, a rectal mucosa without ery-



























Table 1.   Table showing outcome data 
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Patient not having more than 3 well-
formed stools per day and without visi-
ble blood in the stools and any clinical
symptoms of ulcerative colitis and had a

































































Clinical remission, considered in pa-
tient without bloody diarrhoea, with-
out tachycardia, without fever, with-
out anaemia and normal ESR and/or







Unclear   Unclear Unclear Unclear Unclear
Zhang
2018a
Unclear   Unclear Unclear Unclear Unclear
Li 2013 Unclear   Unclear Unclear Unclear 0/20, 0/20,
0/20
Table 1.   Table showing outcome data  (Continued)
Note: steroid withdrawal, biochemical markers of inflammation, histology scores, need for additional therapy, progression to surgery,
clinical scores, and quality of life scores have not been reported in any of the studies.
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DAI: disease activity index; CRP: c-reactive protein; ESR: erythrocyte sedimentation rate; LCAI: Lichtiger colitis activity index; UCDAI:
ulcerative colitis activity index;
 
 
A P P E N D I C E S









8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.




14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. exp ulcerative colitis/
20. colitis.mp.
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33. (bifidus or bifidobacter*).tw.














48. (beneficial adj3 bacter*).tw.
49. (Escherichia coli or "E. coli").tw.
50. Yeast.tw.
51. (fungus or fungi).tw.
52. (VSL# 3 or VSL 3).tw.
53. Or/25-52









8. (singl$ adj blind$).tw.
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45.(Escherichia coli or "E. coli").tw.
46.Yeast.tw.
47.(fungus or fungi).tw.
48.(VSL# 3 or VSL 3).tw.
49.Or/21-48
50.14 and 20 and 49
Cochrane CENTRAL
#1 MeSH descriptor: [Probiotics] explode all trees
#2 MeSH descriptor: [Synbiotics] explode all trees
#3 probiotic*
#4 synbiotic*
#5 MeSH descriptor: [Lactobacillus] explode all trees
#6 lactobacill*
#7 bacill*
#8 MeSH descriptor: [Bifidobacterium] explode all trees
#9 (bifidus or bifidobacter*)
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#10 MeSH descriptor: [Streptococcus thermophilus] explode all trees
#11 streptococcus thermophilus
#12 streptococc*
#13 MeSH descriptor: [Lactococcus] explode all tree
#14 lactococc*
#15 MeSH descriptor: [Bacillus subtilis] explode all trees
#16 bacillus subtilis
#17 MeSH descriptor: [Enterococcus] explode all trees
#18 enterococcus faec*





#24 (Escherichia coli or "E. coli").tw.
#25 Yeast.tw.
#26 (fungus or fungi).tw.
#27 Or/ #1- #26
#28 MeSH: [Ulcerative colitis] explode all trees
#29 UC
#30 Inflammatory bowel disease
#31 IBD
#32 #28 or #29 #30 and #31
#33 #27 and #32
The Cochrane IBD/FBD Review Specialised Trials Register
1. Probiotics and Inflammatory bowel disease
2. Probiotics and Ulcerative colitis
3. Synbiotics and Inflammatory bowel disease
4. Synbiotics and Ulcerative colitis
CINAHL
1. (TI probiotic* or AB probiotic*) OR (TI synbiotic* or AB synbiotic*) OR (TI probiotics* or AB probiotics*) OR (TI lactobacill* or AB
lactobacill*) OR (TI bacill* or AB bacill*) OR (TI bifidobacter* or AB bifidobacter*) OR (TI bifidus* or AB bifidus*) OR (TI streptococc* or AB
streptococc*) OR (TI lactococc* or AB lactococc*) OR (TI enterococcus* or AB enterococcus*) OR (TI saccharomyc* or AB saccharomyc*) OR
(TI leuconostoc* or AB leuconostoc*) OR (TI pediococc* or AB pediococc*) OR (TI *coli or AB *coli) OR (TI yeast* or AB yeast*) OR (TI fung*
or AB fung*) OR (TI VSL* or AB VSL*)
2. (TI Inflammatory bowel disease or AB Inflammatory bowel disease) OR (TI Ulcerative colitis or AB Ulcerative colitis) OR (TI UC or AB UC)
OR (TI IBD or AB IBD)
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3. 1 and 2
ClinicalTrials.gov
1. Probiotics and inflammatory bowel disease (37)
2. Probiotics and Ulcerative colitis (23)
3. Synbiotic and inflammatory bowel disease (3)
4. Synbiotic and Ulcerative colitis (1)
W H A T ' S   N E W
 
Date Event Description
29 November 2019 New citation required and conclusions
have changed
A previous review found no evidence for probiotics (Mallon
2007), whereas this review concludes that probiotics may induce
remission in ulcerative colitis and may enhance rates of remis-
sion when added to 5-aminosalicylic acid (5-ASA) therapy.
31 October 2019 New search has been performed We updated searches in December 2017 and reran them in Octo-
ber 2019; we added 10 new studies to this update.
 
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 4, 2007
 
Date Event Description
15 May 2008 Amended Converted to new review format




C O N T R I B U T I O N S   O F   A U T H O R S
Lakhbir Kaur took the lead in writing the review, extracted data and contacted authors; checked the quality of data extraction; analysed and
interpreted data; undertook and checked quality assessment; performed statistical analysis; checked the quality of the statistical analysis;
produced the first draT of the review; contributed to writing and editing the review; made an intellectual contribution to the review; and
approved the final review prior to submission.
Morris Gordon performed screening of titles and abstracts and full-text articles, data extraction and contacted authors, analysed and
interpreted data; contributed to writing and editing the review; made an intellectual contribution to the review; contributed to previous
versions of the review; and approved the final review prior to submission.
Patricia Baines contributed to writing and editing the review; made an intellectual contribution to the review; and approved the final review
prior to submission.
Zipporah Iheozor-Ejiofor extracted data; checked the quality of data extraction; analysed and interpreted data; checked quality
assessment; checked the quality of statistical analysis; contributed to writing and editing the review; made an intellectual contribution to
the review; and approved the final review prior to submission.
Vasiliki Sinopoulou made update changes to all sections of the review following peer review and repeated searches; and approved the
final review.
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Anthony Akobeng initiated and conceptualised the review; contributed to the previous versions of the review; and approved the final
review prior to submission.
D E C L A R A T I O N S   O F   I N T E R E S T
Lakhbir Kaur: none known
Morris Gordon: received travel grants from various companies to attend scientific meetings in the last three years, including Biogaia,
Synergy, Tillots, Ferring and Allergan. None of these companies have had any involvement in the planning, completion, analysis or write up
of this or any other reviews. This review has been completed as part of a UK funded National Institute for Health Research (NIHR) Cochrane
Programme grant, with some time funded.
Patricia Baines: none known
Zipporah Iheozor-Ejiofor: my employment at the University of Central Lancashire is funded by the National Institute for Health Research
(NIHR) UK and focuses on high-priority Cochrane Reviews in inflammatory bowel disease.
Vasilliki Sinopoulou: none known
Anthony Akobeng: none known
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In this update, we redesigned the search strategies and updated the risk of bias and GRADE in line with current Cochrane approaches.
We updated the consideration of adverse events to take into account the three key forms used across Cochrane Inflammatory Bowel
Disease (minor adverse events, serious adverse events, withdrawal due to adverse events).
We also included children, who had previously been excluded.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Colitis, Ulcerative  [*diet therapy];  Probiotics  [*therapeutic use];  Randomized Controlled Trials as Topic;  Remission Induction
MeSH check words
Humans
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